All-In: The 23-Stock Six-Figure Dividend Portfolio I'm Betting My Future On
- Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend stocks. Focused on wide-moat businesses, I prioritize quality and long-term growth over yield. My portfolio has outperformed the S&P 500, and I'm confident in its future. I expect a rotation to value stocks, and I'll keep sharing insights to grow together.
- 02/14/2025
|
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
- DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
- 02/13/2025
|
3 Top Value Stocks to Buy and Hold for 2025
- These high-quality companies are solid—and their stocks look cheap.
- 02/11/2025
|
Where I'd Put $10,000 Right Now - My Best Dividend Picks For Income And Growth
- I started investing with a modest $4,000, now growing it into a 23-stock portfolio. The median net worth varies by age, but most can invest $10,000 for growth. The goal here isn't to push random picks, but to offer long-term dividend ideas. I connect my choices to the broader economic picture, from undervalued essentials to GARP stocks. In this article, I highlight undervalued consumer staples, GARP stocks, and investment ideas linked to potential political changes, all aimed at steady dividend growth.
- 02/10/2025
|
Danaher Analysts Cut Their Forecasts After Downbeat Earnings
- Danaher Corporation DHR reported weaker-than-expected fourth-quarter earnings on Wednesday.
- 01/30/2025
|
Danaher Q4 Earnings Miss Estimates, Life Sciences Sales Rise Y/Y
- DHR's fourth-quarter sales increase 2.1% year over year, benefiting from the solid performance of its Life Sciences and Biotechnology segments.
- 01/29/2025
|
Danaher (DHR) Reports Q4 Earnings: What Key Metrics Have to Say
- The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 01/29/2025
|
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
- Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
- 01/29/2025
|
Danaher (DHR) Lags Q4 Earnings Estimates
- Danaher (DHR) came out with quarterly earnings of $2.14 per share, missing the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.09 per share a year ago.
- 01/29/2025
|
Danaher misses quarterly profit estimates on weak biotech demand
- Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients.
- 01/29/2025
|
Danaher Reports Fourth Quarter and Full Year 2024 Results
- WASHINGTON , Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted.
- 01/29/2025
|
MARUY vs. DHR: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Diversified Operations stocks have likely encountered both Marubeni Corp. (MARUY) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
- 01/28/2025
|
Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?
- DHR's Q4 results are likely to be ailed by weakness in the Biotechnology and Life Sciences segments.
- 01/24/2025
|
Danaher (DHR) Earnings Expected to Grow: Should You Buy?
- Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/22/2025
|
Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
- FARGO, N.D.--(BUSINESS WIRE)--Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications.
- 01/21/2025
|
Danaher: Transition Year Recap
- Danaher faced a disappointing 2024, despite beating Q3 expectations, due to unaltered full-year guidance and a significant asset writedown. The company executed a $4.5 billion share buyback, with an additional 20 million shares authorized, reflecting confidence in long-term growth. Danaher's ROIC appears low due to heavy R&D and capex investments, but this expands its competitive moat and deters new entrants.
- 01/16/2025
|
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
- In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable dividend stocks thrive despite volatility, offering steady income and solid growth in uncertain times. Building a balanced portfolio of 10 carefully selected SWAN stocks ensures consistent returns. This strategy offers peace of mind, regardless of market fluctuations.
- 01/16/2025
|
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
- New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif. , Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only (RUO) blood-based biomarker immunoassays designed to advance neurodegenerative disease research.
- 01/15/2025
|
Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
- Danaher Corporation (NYSE:DHR ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2024 2:15 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - J.P.
- 01/14/2025
|
Danaher CEO to Comment on Financial Performance
- WASHINGTON , Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P.
- 01/13/2025
|
Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth
- Seeking Alpha's Quant Valuation and Growth Grades identify 6 blue-chip stocks with extremely high valuations matched against limited operating growth potential. Costco, Cencora, West Pharmaceutical Services, Danaher, Madison Square Garden Sports, and Estée Lauder appear to be at risk of disappointing investors in 2025. Weakening technical performance vs. the S&P 500 is part of the bearish sell/avoid equation for each since summer.
- 01/13/2025
|
Danaher Announces Investment Partnership in Innovaccer Inc.
- Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions. Investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.
- 01/09/2025
|
Danaher to Present at J.P. Morgan Healthcare Conference
- WASHINGTON , Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
- 01/06/2025
|
Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
- Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors.
- 01/06/2025
|
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
- Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/03/2025
|
Danaher Schedules Fourth Quarter 2024 Earnings Conference Call
- WASHINGTON , Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour.
- 01/02/2025
|
3 of the Best Companies to Own in 2025 and Beyond
- #Morningstar #BestStockstoInvestIn #StockInvesting These companies have durable competitive advantages and generate reliable cash flows. 00:00 Introduction 00:46 Danaher DHR 01:36 Paychex PAYX 02:17 Equifax EFX I'm Susan Dziubinski with Morningstar.
- 12/17/2024
|
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
- Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "Magic Formula" and James O'Shaughnessy's methodologies to screen stocks based on earnings yield and return on total capital. Exclude overly regulated sectors like Utilities, Financials, and REITs to focus on sectors with higher growth potential and less regulatory constraints.
- 12/13/2024
|
Danaher Announces Quarterly Dividend
- WASHINGTON , Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on January 31, 2025 to holders of record on December 27, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.
- 12/10/2024
|
Here's Why You Should Avoid Investing in Danaher Stock Right Now
- DHR experiences weakness in its operations due to softness in the Life Sciences segment. Rising expenses are added concerns.
- 12/10/2024
|
Danaher: A Resilient And Solid Company With Growth Potential
- Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduced their excess of COVID-19-related products. So, Danaher expects a further boost in its sales.
- 12/10/2024
|
Danaher Corporation (DHR) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
- Danaher Corporation (NYSE:DHR ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 3:25 PM ET Company Participants Rainer Blair - President and CEO Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon.
- 12/05/2024
|
Danaher to Present at Evercore ISI HealthCONx Conference
- WASHINGTON , Nov. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Wednesday, December 4, 2024 at 3:25 p.m.
- 11/26/2024
|
Revving Up: 2 Underperforming Dividend Giants Ready To Outshine
- Two high-quality dividend stocks are finally positioned for a strong rebound. After a period of underperformance, their growth potential is back in focus. These companies have adapted well to recent challenges, enhancing their strategies to boost shareholder returns. Their fundamentals are solid and undervalued. With robust dividends and renewed growth trajectories, both stocks stand ready to outperform. Ideal picks for investors seeking stability and upside potential.
- 11/14/2024
|
Danaher (DHR) Reliance on International Sales: What Investors Need to Know
- Examine Danaher's (DHR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
- 10/28/2024
|
Want to Grow a Passive Income Snowball? Buy These 7 Elite Dividend Growth Stocks.
- These seven companies are transforming steady profits into rising passive income streams for investors.
- 10/26/2024
|
Understanding Danaher's Cautiousness
- Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positive, but management seems reluctant to put numbers around their optimism. There might be a reason behind the conservativeness, which I explain in this article.
- 10/25/2024
|
Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating
- On Tuesday, Danaher Corp DHR reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion.
- 10/22/2024
|
Danaher Q3 Earnings Surpass Estimates, Diagnostics Sales Up Y/Y
- DHR's third-quarter earnings and sales surpass estimates, benefiting from the solid performance of its Life Sciences and Diagnostics segments.
- 10/22/2024
|
Stock Markets Taper on High Valuations, Upcoming Election
- In two weeks we potentially could see a number of prominent news items which could change the trajectory of stock market enthusiasm.
- 10/22/2024
|
Danaher Corporation (DHR) Q3 2024 Earnings Call Transcript
- Danaher Corporation (NYSE:DHR ) Q3 2024 Earnings Call Transcript October 22, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Conference Call Participants Tycho Peterson - Jefferies Michael Ryskin - Bank of America Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Scott Davis - Melius Research Puneet Souda - Leerink Partners Dan Leonard - UBS Jack Meehan - Nephron Research Operator My name is Ashley and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's Third Quarter 2024 Earnings Results Conference Call.
- 10/22/2024
|
Danaher (DHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- While the top- and bottom-line numbers for Danaher (DHR) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 10/22/2024
|
Danaher (DHR) Tops Q3 Earnings and Revenue Estimates
- Danaher (DHR) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $2.02 per share a year ago.
- 10/22/2024
|
Danaher beats quarterly profit estimates on strong demand for bioprocessing unit
- Danaher on Tuesday beat Wall Street estimates for third-quarter profit on strong demand for its diagnostics and bioprocessing businesses, alongside growth in its molecular testing unit.
- 10/22/2024
|
Danaher Reports Third Quarter 2024 Results
- WASHINGTON , Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted.
- 10/22/2024
|
Exploring Analyst Estimates for Danaher (DHR) Q3 Earnings, Beyond Revenue and EPS
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Danaher (DHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
- 10/17/2024
|
Cramer's Mad Dash: Danaher
- CNBC's Jim Cramer delivers his daily Mad Dash.
- 10/17/2024
|
Danaher to Benefit From Business Strength Amid Headwinds
- DHR stands to benefit from strength in the clinical diagnostics business, Abcam buyout and shareholder-friendly policies. Softness in the Instrument unit remains a concern.
- 10/11/2024
|
3 Dividend Titans With Pricing Power Straight From The Hedge Fund Playbook
- Learning from successful hedge funds like Millennium means focusing on minimizing risks. To achieve this, I focus on companies with strong pricing power. They have wide moats and recurring revenue that help protect against economic downturns. I've identified three dividend stocks that stand out for their pricing power, market leadership, and ability to generate sustainable long-term returns.
- 10/01/2024
|
Danaher Q3 Preview: Market Share Gains In Molecular Testing
- I reiterate my 'Strong Buy' rating for Danaher, with a one-year price target of $310 per share, citing recovery in bioprocessing and market share gains in molecular testing. Danaher's bioprocessing market shows high-single-digit growth in orders, with stabilization in China, and is expected to sustain recovery in Q3 and FY25. Cepheid's market share gains in molecular testing, including FDA authorization for its Hepatitis C RNA test, highlight Danaher's innovation and growth potential.
- 09/25/2024
|
Automated and Closed Cell Therapy Market Research 2024-2029 Featuring Leading Players - Danaher, Thermo Fischer Scientific, Lonza, and Sartorius
- Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Automated and Closed Cell Therapy Market 2024-2029" report has been added to ResearchAndMarkets.com's offering.
- 09/24/2024
|
The Ultimate 5: My Highest-Conviction Dividend Stocks
- I explore the idea of managing a highly concentrated portfolio and share how I narrowed down my highest-conviction dividend investments to just five stocks. I emphasize the importance of choosing reliable companies, future-proof wealth compounders, even in a compact portfolio with limited stock picks. After careful analysis, I present my top five dividend stocks, each chosen for their unique qualities, strong growth potential, and ability to thrive long-term.
- 09/24/2024
|
Danaher Schedules Third Quarter 2024 Earnings Conference Call
- WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m.
- 09/19/2024
|
The Big 3: ANET, MET, DHR
- Today's Big 3 looks at companies trading at or near their 52-week highs but show very different long-term charts. Dan Deming joins Diane King Hall and Ben Lichtenstein to break down the technical trends of Arista Networks (ANET), MetLife (MET), and Danaher (DHR).
- 09/19/2024
|
Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
- BREA, Calif. and TEL AVIV, Israel , Sept.
- 09/17/2024
|
Danaher Announces Quarterly Dividend
- WASHINGTON , Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024.
- 09/10/2024
|
Here's Why It is Appropriate to Retain Danaher Stock For Now
- DHR benefits from solid momentum across its Diagnostics segment. However, increasing expenses remain a concern.
- 09/10/2024
|
Danaher Confirms Third Quarter and Full Year 2024 Guidance
- WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.
- 09/04/2024
|
HTHIY or DHR: Which Is the Better Value Stock Right Now?
- Investors with an interest in Diversified Operations stocks have likely encountered both Hitachi Ltd. (HTHIY) and Danaher (DHR).
- 08/27/2024
|
Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.
- WASHINGTON , Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m.
- 08/26/2024
|
Danaher: Lofty Price, Bright Future
- Danaher's high valuation and flat 2024 EPS growth might raise eyebrows, but its track record, strategic acquisitions, and long-term growth potential make it a solid buy for those who can. Despite trading at a premium, Danaher's strong history, efficient operations, and potential for double-digit EPS growth in 2025 make it one of the few stocks I'm buying at a lofty price. Danaher's blend of strategic acquisitions and operational efficiency makes it a long-term winner. I'm adding to my position despite the high P/E, expecting strong returns as growth picks up.
- 08/22/2024
|
Why Is Danaher (DHR) Up 2% Since Last Earnings Report?
- Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
- 08/22/2024
|
Danaher (DHR) Benefits From Business Strength Amid Risks
- Danaher (DHR) benefits from strength in the clinical diagnostics business, Abcam buyout and pro-investor policies. However, softness in its Instrument unit is concerning.
- 08/16/2024
|
Betting Big: 3 Dividend Stocks My Family And I Are Buying Aggressively
- Market corrections happen under almost every president, and stock performance is not tied to political parties. Currently, inflation remains the key driver of market movements. Focus on undervalued opportunities in any market condition. Consistent investment in solid stocks is more effective than trying to time the market. Three key stocks in our portfolios demonstrate resilience and growth potential, offering a mix of dividend growth and value despite current market challenges.
- 07/30/2024
|
HTHIY or DHR: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Diversified Operations sector might want to consider either Hitachi Ltd. (HTHIY) or Danaher (DHR).
- 07/26/2024
|
Final Trades: Freeport-McMoran, Pfizer, Danaher and United Rentals
- The Investment Committee give you their top stocks to watch for the second half.
- 07/25/2024
|
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration
- BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the DxI 9000 Immunoassay Analyzer* was honored during Premier, Inc.'s annual supplier Innovation Celebration at its 2024 Breakthroughs Conference and Exhibition.
- 07/25/2024
|
Danaher (DHR) Q2 Earnings Beat, Biotechnology Sales Dip Y/Y
- Danaher's (DHR) second-quarter earnings and revenues surpass estimates. However, the company's performance reflects a decrease in core sales in the Biotechnology segment.
- 07/23/2024
|
Danaher Stock Soars on Q2 Earnings Beat
- Danaher Corp. (DHR) beat analysts' expectations on the top and bottom lines with its second-quarter results, sending shares higher in intraday trading Tuesday.
- 07/23/2024
|
Here's Why Danaher Stock Surged Today
- The pandemic has created a lot of noise around Danaher's revenue growth, but the dust looks set to settle in 2024. Core revenue and margins were better than expected in the second quarter.
- 07/23/2024
|
Here's What Key Metrics Tell Us About Danaher (DHR) Q2 Earnings
- The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 07/23/2024
|
Danaher Corporation (DHR) Q2 2024 Earnings Call Transcript
- Danaher Corporation (NYSE:DHR ) Q2 2024 Earnings Conference Call July 23, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer M. Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Jack Meehan - Nephron Research Rachel Vatnsdal - J.P.
- 07/23/2024
|
Danaher Stock Surges. More Than Earnings Are Driving It Higher.
- Danaher reports second-quarter adjusted earnings of $1.72 a share on revenue of $5.74 billion.
- 07/23/2024
|
Danaher (DHR) Q2 Earnings and Revenues Beat Estimates
- Danaher (DHR) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $2.05 per share a year ago.
- 07/23/2024
|
Danaher beats Q2 profit estimates on strength in medical testing business
- Danaher beat Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its genetic testing services, sending shares of the life sciences firm up nearly 8% in premarket trading.
- 07/23/2024
|
Danaher Reports Second Quarter 2024 Results
- WASHINGTON , July 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted.
- 07/23/2024
|
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
- Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/19/2024
|
Danaher Q2: Inventory Overhang, But Low Expectations Limit Downside
- Danaher Corporation stock saw a high single-digit percentage increase from April to mid-June, but has since given up most of the gains. Concerns about inventory destocking in the bioprocessing market have impacted investor sentiment, but expectations are already priced in. Despite short-term challenges, Danaher's medium to long-term prospects remain positive, with good growth starting FY25.
- 07/19/2024
|
Danaher (DHR) Gears Up to Post Q2 Earnings: What to Expect
- Danaher's (DHR) second-quarter earnings are likely to be aided by strength in the Diagnostics and Life Sciences segment.
- 07/18/2024
|
Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development
- DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.
- 07/17/2024
|
Danaher (DHR) Upgraded to Buy: Here's What You Should Know
- Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 07/16/2024
|
Is Danaher (DHR) Stock Outpacing Its Conglomerates Peers This Year?
- Here is how Danaher (DHR) and Honeywell International Inc. (HON) have performed compared to their sector so far this year.
- 07/16/2024
|
Danaher Releases 2024 Sustainability Report
- WASHINGTON , July 16, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year. "At the heart of everything we do at Danaher is our commitment to continuous improvement, and our sustainability program exemplifies this commitment," said Rainer Blair, President and Chief Executive Officer.
- 07/16/2024
|
Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening
- Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies.
- 07/11/2024
|
Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer
- Ideally Suited for Satellite and Independent Labs, the new DxC 500i Analyzer Offers Flexibility, Scalability and Data Commutability with Extensive Chemistry and Immunoassay Assay Menu The New DxC 500i Analyzer Incorporates Recently Introduced DxC 500 AU Chemistry Analyzer Technology with Six Sigma Performance BREA, Calif. , July 9, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today introduces the new DxC 500i Clinical Analyzer*, an integrated clinical chemistry and immunoassay analyzer.
- 07/09/2024
|
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
- Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.
- 06/28/2024
|
Danaher Schedules Second Quarter 2024 Earnings Conference Call
- WASHINGTON , June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour.
- 06/24/2024
|
Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics
- WASHINGTON , June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.
- 06/19/2024
|
Global Flow Cytometry Industry Outlook Report, 2024-2032: Market Dynamics, Technology Insights, Patent Analysis (2014-2024), and Profiles of Leading Players Including BD and Danaher
- Dublin, June 19, 2024 (GLOBE NEWSWIRE) -- The "Global Flow Cytometry Market by Technology (Cell-based, Bead-Based), Product & Service (Analyzer, Sorter, Consumables (Antibodies, Assays, Kits), Software), Application (Research (Immunology, Stem Cell, Apoptosis), Clinical (Cancer)) - Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. The global flow cytometry market is estimated to reach USD 10.3 billion by 2032 from USD 5.1 billion in 2024, at a CAGR of 9.2% during the forecast period of 2024 to 2032. Advancements in reagent technologies, such as fluorophore conjugation and specificity enhancement is one of the major factor uplifting the market growth. The dominance of the reagents and consumables segment among product and services factors is notable in the flow cytometry market. This segment holds sway due to continuous demand for antibodies, dyes, and other consumables essential for cell analysis. As the use of flow cytometry expands in research, clinical diagnostics, and drug development, the need for high-quality reagents remains constant.
- 06/19/2024
|
Here's Why Hold Strategy Is Apt for Danaher (DHR) Stock Now
- Strength in the Life Sciences segment augurs well for Danaher (DHR). The company's measures to reward its shareholders are promising.
- 06/14/2024
|
Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer
- Move reflects increasing investment in AI as driving force for innovation and productivity. Company will host Innovation Summit in December focused on AI in R&D.
- 06/05/2024
|
Why Is Danaher (DHR) Up 6.7% Since Last Earnings Report?
- Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
- 05/23/2024
|
Lab Instrument Industry Update - New Commercial Entrants
- Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
- 05/23/2024
|
Danaher (DHR) Rides on Business Strength Amid Headwinds
- Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
- 05/15/2024
|
Danaher Corporation (DHR) Presents at BofA Securities 2024 Health Care Conference Call Transcript
- Sirius XM Holdings Inc. (SIRI) BofA Securities 2024 Health Care Conference Call May 14, 2024 1:40 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Michael Ryskin - Bank of America Michael Ryskin Everyone will kick things off for our next session. My name is Mike Ryskin.
- 05/14/2024
|
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
- The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics.
- 05/09/2024
|
Danaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
- Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 05/08/2024
|
Danaher to Present at Bank of America Securities Healthcare Conference
- WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Tuesday, May 14, 2024 at 10:40 a.m.
- 05/07/2024
|
Danaher Announces Quarterly Dividend
- WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 26, 2024 to holders of record on June 28, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.
- 05/07/2024
|
Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry
- WOBURN, Mass. , May 3, 2024 /PRNewswire/ -- Curiox Biosystems Co. Ltd (Curiox), a leader in the innovation of life science research technologies, and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announce a strategic partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry.
- 05/03/2024
|
The Forgotten Stock Advice That Delivers 170%+ Payout Growth
- One of the best ways to grab a dividend payer set to surge is a strategy you never hear about anymore: Pick up shares of a conglomerate.
- 05/01/2024
|
What Should You Do With Danaher Stock At $250 After Q1 Beat?
- Danaher stock (NYSE: DHR), a conglomerate with products in life sciences, biotechnology, and diagnostics fields, recently posted its Q1 results that exceeded the street expectations. The company reported revenue of $5.8 billion and adjusted earnings of $1.92 per share, compared to the consensus estimates of $5.3 billion and $1.60, respectively.
- 04/26/2024
|
Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y
- While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.
- 04/23/2024
|
Earnings Today: PulteGroup, Danaher Rally; JetBlue Dives
- PulteGroup received an added data boost, Danaher's markets are looking up, and JetBlue collapses, despite a not-as-bad-as-feared loss.
- 04/23/2024
|
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 04/23/2024
|
Danaher Shrugs Off Outlook for Falling Sales
- The medical company reported first-quarter adjusted earnings of $1.92 a share, beating Wall Street's call for $1.72.
- 04/23/2024
|
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
- Danaher (DHR) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.72 per share. This compares to earnings of $2.36 per share a year ago.
- 04/23/2024
|
Danaher beats quarterly estimates on strength in diagnostics business
- Danaher beat quarterly profit and sales expectations on Tuesday, driven by strength in its diagnostics and bioprocessing businesses, sending shares of the life sciences firm up more than 7% before the bell.
- 04/23/2024
|
Danaher Reports First Quarter 2024 Results
- WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted.
- 04/23/2024
|
Why Danaher (DHR) Might Surprise This Earnings Season
- Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 04/19/2024
|
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
- Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/18/2024
|
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
- Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
- 04/18/2024
|
Curious about Danaher (DHR) Q1 Performance? Explore Wall Street Estimates for Key Metrics
- Evaluate the expected performance of Danaher (DHR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 04/18/2024
|
Suddenly, There's An Alternative - The Important Case For Wide Moat Dividend Stocks
- Short-term bonds currently yield more than stocks, indicating a shift in the investment environment. Investors should focus on companies with healthy balance sheets, pricing power, and that are trading below their fair value. We suggest several favorite wide-moat dividend businesses.
- 04/18/2024
|
Reasons Why Danaher (DHR) Should be in Your Portfolio Now
- Danaher (DHR) is set to benefit from strength across its businesses, acquired assets and shareholder-friendly policies.
- 04/12/2024
|
Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for April 2024
- Healthcare's impact on the economy cannot be overstated. According to the American Medical Association, the U.S. spends more than $4 trillion a year on healthcare, which works out to nearly $13,000 per person.
- 04/11/2024
|
Here's Why Danaher (DHR) Gained But Lagged the Market Today
- In the closing of the recent trading day, Danaher (DHR) stood at $244.28, denoting a +0.98% change from the preceding trading day.
- 04/05/2024
|
Investors Heavily Search Danaher Corporation (DHR): Here is What You Need to Know
- Danaher (DHR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 04/04/2024
|
Danaher (DHR) Suffers a Larger Drop Than the General Market: Key Insights
- In the closing of the recent trading day, Danaher (DHR) stood at $245.94, denoting a -0.75% change from the preceding trading day.
- 04/02/2024
|
Danaher (DHR) Rises Yet Lags Behind Market: Some Facts Worth Knowing
- Danaher (DHR) reachead $248.77 at the closing of the latest trading day, reflecting a +0.12% change compared to its last close.
- 03/27/2024
|
Wall Street Analysts See Danaher (DHR) as a Buy: Should You Invest?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 03/27/2024
|
Danaher: All In On Life Sciences, And Market Update
- Danaher Corporation is a leading player in the life science industry, with strong financial performance despite many spin-offs. The healthcare industry is facing challenges due to weak funding and high vacancy rates in lab spaces, but there are signs of a turnaround. While the valuation is rising, I believe investors can still take advantage of the momentarily weak market opportunity.
- 03/27/2024
|
Danaher Schedules First Quarter 2024 Earnings Conference Call
- WASHINGTON , March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour.
- 03/21/2024
|
Here is What to Know Beyond Why Danaher Corporation (DHR) is a Trending Stock
- Zacks.com users have recently been watching Danaher (DHR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 03/21/2024
|
Danaher (DHR) Stock Declines While Market Improves: Some Information for Investors
- The latest trading day saw Danaher (DHR) settling at $251.68, representing a -0.81% change from its previous close.
- 03/20/2024
|
Why Danaher (DHR) Outpaced the Stock Market Today
- The latest trading day saw Danaher (DHR) settling at $251.47, representing a +0.83% change from its previous close.
- 03/18/2024
|
Danaher (DHR) Benefits From Business Strength Amid Risks
- Danaher (DHR) gains from strength in academic and life science research markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology and Diagnostics units is concerning.
- 03/13/2024
|
Why Danaher (DHR) Dipped More Than Broader Market Today
- Danaher (DHR) closed the most recent trading day at $252.80, moving -0.35% from the previous trading session.
- 03/11/2024
|
Is Trending Stock Danaher Corporation (DHR) a Buy Now?
- Danaher (DHR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 03/01/2024
|
Why Is Danaher (DHR) Up 6.6% Since Last Earnings Report?
- Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
- 02/29/2024
|
Why the Market Dipped But Danaher (DHR) Gained Today
- Danaher (DHR) reachead $255.71 at the closing of the latest trading day, reflecting a +0.33% change compared to its last close.
- 02/28/2024
|
ITT Q4 Earnings In Line With Estimates, Revenues Increase Y/Y
- ITT's Q4 revenues increase 7% year over year, driven by higher Friction original equipment volumes in the Motion Technologies segment and pricing actions in the Connect & Control Technologies segment.
- 02/09/2024
|
Danaher (DHR) Q4 Earnings Beat, Biotechnology Sales Dip Y/Y
- While Danaher (DHR) surpasses Q4 earnings and revenue estimates, its performance is hurt by a decrease in the sale of COVID-related products and weak demand in the Biotechnology segment.
- 01/30/2024
|
Danaher (DHR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 01/30/2024
|
Danaher (DHR) Surpasses Q4 Earnings and Revenue Estimates
- Danaher (DHR) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.90 per share. This compares to earnings of $2.87 per share a year ago.
- 01/30/2024
|
Why Danaher (DHR) Might Surprise This Earnings Season
- Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 01/29/2024
|
Danaher (DHR) Gears Up to Post Q4 Earnings: Is a Beat in Store?
- Danaher's (DHR) Q4 earnings are likely to have been hurt by weakness in the Biotechnology and Diagnostics units owing to lower sales of COVID-related products. Improving supply chains and strong price realization are expected to have been positives.
- 01/26/2024
|
Seeking Clues to Danaher (DHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Danaher (DHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
- 01/25/2024
|
Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/23/2024
|
Why Danaher (DHR) is Poised to Beat Earnings Estimates Again
- Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/17/2024
|
Charts turn bullish on health-care stocks as sector takes early lead in 2024
- Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts have cited attractive valuations relative to earnings and a compelling growth story as two reasons health-care stocks might continue to outperform.
- 01/16/2024
|
Danaher (DHR) Stock Declines While Market Improves: Some Information for Investors
- Danaher (DHR) closed the most recent trading day at $229.64, moving -0.53% from the previous trading session.
- 01/10/2024
|
Will Danaher stock hit new highs in 2024?
- Danaher Corporation NYSE: DHR shares went into a tailspin when the Abcam deal came into question, but the dip turned out to be a buying opportunity in this life-sciences company. The dip hit bottom soon after, and even weak guidance could not lower the market.
- 01/10/2024
|
Here's Why Danaher (DHR) Fell More Than Broader Market
- The latest trading day saw Danaher (DHR) settling at $230.81, representing a -1.7% change from its previous close.
- 01/03/2024
|
Danaher to Present at J.P. Morgan Healthcare Conference
- WASHINGTON , Jan. 2, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
- 01/02/2024
|
Investor Michael Farr is back with his top 10 stocks he's buying for 2024, and the tilt is defensive
- This year's list is a bit more defensive than in years past and has a focus on earnings growth.
- 12/28/2023
|
Danaher: Continuously Compounding
- Danaher has undergone a radical transformation from a real estate trust to a leader in the life sciences industry through strategic acquisitions. The company's focus on continuous improvement and efficiency, guided by the Kaizen philosophy, has been a driving force behind its success. Danaher's recent divestments and increased focus on its core businesses have led to strong financial performance and growth, making it an attractive investment option.
- 12/28/2023
|
My Top 2024 Stock Pick: Danaher
- Danaher is my low-risk SWAN stock pick for 2024, with a strong track record of growth and a focus on rational, data-driven decision-making at its core. The end market for Danaher's healthcare and bioprocessing products is expected to return to growth, driven by new technology and increased funding. The spin-off of certain segments and potential future acquisitions, as well as operational improvements and new growth opportunities for Danaher, should increase cash flows over time.
- 12/27/2023
|
Top 3 Healthcare Stock Picks for the New Year
- After lagging most sectors in 2023, healthcare stocks could deliver substantial returns in 2024. The market has been overly pessimistic about the sector due to short-term challenges.
- 12/25/2023
|
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
- WASHINGTON , Dec. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour.
- 12/21/2023
|
Reasons to Retain Danaher (DHR) Stock in Your Portfolio Now
- Strength in the Life Sciences segment and accretive acquisition bode well for Danaher (DHR). The company's measures to reward its shareholders are encouraging.
- 12/19/2023
|
Danaher (DHR) Stock Falls Amid Market Uptick: What Investors Need to Know
- Danaher (DHR) closed the most recent trading day at $226.45, moving -0.34% from the previous trading session.
- 12/18/2023
|
Danaher (DHR) Surpasses Market Returns: Some Facts Worth Knowing
- Danaher (DHR) concluded the recent trading session at $221.35, signifying a +1.77% move from its prior day's close.
- 12/11/2023
|
Danaher (DHR) Acquires Abcam to Boost Life Sciences Segment
- Danaher (DHR) acquires Abcam for $5.7 billion, thus adding to its Life Sciences portfolio. This move will facilitate the mapping of complex diseases and expedite the drug discovery process.
- 12/07/2023
|
Danaher completes $5.7 billion acquisition of Abcam
- Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.
- 12/06/2023
|
Danaher (DHR) Declines More Than Market: Some Information for Investors
- The latest trading day saw Danaher (DHR) settling at $219.44, representing a -1.21% change from its previous close.
- 12/05/2023
|
Danaher (DHR) Ascends While Market Falls: Some Facts to Note
- Danaher (DHR) concluded the recent trading session at $222.52, signifying a +1.72% move from its prior day's close.
- 11/29/2023
|
Danaher Corporation (DHR) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
- Danaher Corporation (NYSE:DHR ) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 3:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Thanks, everyone, for joining us this afternoon. A pleasure to have with us, Danaher.
- 11/29/2023
|
Danaher Corporation: A Good Contrarian Bet
- Danaher Corporation is facing near-term headwinds due to COVID-19-related demand normalization and customer inventory destocking in its Biotechnology segment. However, these headwinds are temporary, and the company's medium to long-term growth story is attractive. The company has a healthy balance sheet, strong exposure to high-growth end markets like Biologics, and a history of driving shareholder value through portfolio transformation and strategic M&A.
- 11/27/2023
|
Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles
- Danaher focuses on innovation for steady, high-value recurring revenue, driving financial stability. Aging population, longer lifespans, and tech advances drive Danaher's sector toward significant growth. I expect a 10% revenue dip from lowered COVID-19 product sales, with recovery projected in 12 months.
- 11/26/2023
|
3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape
- The U.S. continues to spend more money on healthcare than any other country. Healthcare spending totaled $4.3 trillion, according to the American Medical Association.
- 11/22/2023
|
Danaher to Present at Evercore ISI HealthCONx Conference
- WASHINGTON , Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023 at 3:00 p.m.
- 11/21/2023
|
Last Call: 3 Growth Stocks to Buy Before New Year's Eve
- In the shifting sands of the current stock market, discerning investors continue to navigate a labyrinth of uncertainties. Yet, the allure of long-term growth stocks remains undiminished.
- 11/19/2023
|
Three value stock picks from a veteran manager with a good performance record
- For many years through 2022, it was becoming more difficult for active fund managers to make the case for their services, when broad index funds, with lower fees, were performing so well. But the tech-driven market decline for 2022 might have made some investors think again about different investment styles for the long term.
- 11/08/2023
|
A New Bull Market Is Coming! 3 Stocks Set to Soar 65% to 132% Higher
- Regardless of whether you're a Wall Street veteran or new to investing, the past four years have been a roller coaster ride. A global pandemic brought a 14-year-long bull market to a screeching halt.
- 11/01/2023
|
Make Me a Millionaire: 3 Top Growth Stocks to Buy Now
- The stock market is on the downswing. Many traders are dumping their holdings as inflation, interest rates, and geopolitical crises weigh heavily on sentiment.
- 11/01/2023
|
Danaher's (DHR) Q3 Earnings & Revenues Beat, Decline Y/Y
- While Danaher (DHR) surpasses Q3 earnings and revenue estimates, the company's performance is hurt by a decrease in the sale of COVID-related products and weak demand in the Life Sciences segment.
- 10/24/2023
|
Danaher 3Q earnings beat but shares fall on disappointing outlook
- Danaher (NYSE:DHR)'s third quarter earnings topped Wall Street estimates on the top and bottom lines but its weak guidance saw investors retreat from the stock. The company - which designs, manufactures and markets products and services across a range of industries including medical and industrial – reported a 10.5% year-over-year drop in revenue to $6.9 billion.
- 10/24/2023
|
Hey, Warren! 3 Stocks Buffett Should Buy Now.
- Everyone in the business media has a suggestion or two of what stocks Warren Buffett should buy or companies Berkshire Hathaway (NYSE: BRK-A , NYSE: BRK-B ) ought to acquire. I've written several articles about Warren Buffett stocks in the past year.
- 10/24/2023
|
Danaher Corporation (DHR) Q3 2023 Earnings Call Transcript
- Danaher Corporation (NYSE:DHR ) Q3 2023 Earnings Conference Call October 24, 2023 8:00 AM ET Company Participants John Bedford - Vice President of Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Vijay Kumar - Evercore ISI Scott Davis - Melius Research Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Rachel Vatnsdal - JPMorgan Operator Good morning. My name is Todd, and I will be your conference facilitator today.
- 10/24/2023
|
Danaher (DHR) Surpasses Q3 Earnings and Revenue Estimates
- Danaher (DHR) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $2.56 per share a year ago.
- 10/24/2023
|
Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.
- Danaher posts third-quarter earnings of $2.02 a share on revenue of $6.87 billion.
- 10/24/2023
|
7 Stocks to Buy Before They Become the Next Trillion-Dollar Companies: October Edition
- The trillion-dollar valuation club is not an easy one to reach. In fact, a grand total of just nine companies have reached this figure to-date.
- 10/19/2023
|
Will Diagnostic Unit Weakness Mar Danaher's (DHR) Q3 Earnings?
- Danaher's (DHR) Q3 results are likely to be hurt by weakness in the Biotechnology and Diagnostics segments due to a decrease in the sale of COVID-related products.
- 10/16/2023
|
Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short
- In an exclusive interview with Thomas Warner (TW) of Proactive London, Dr Jonathan Milner (JM), the founder of life sciences company Abcam PLC (NASDAQ:ABCM), discusses why he believes the $24 per share acquisition offer from Danaher (NYSE:DHR) severely undervalues the company. Milner criticises the timing of the deal and advises shareholders to consider whether the $5.7 billion acquisition is in their best interest.
- 10/16/2023
|
IPOs are out of fashion. Here's what companies are doing instead.
- While the current deal landscape on Wall Street remains low on M&A, initial public offerings (IPOs), and other transactions, corporate spinoffs are chugging along.
- 10/06/2023
|
Veralto: Thoughts On The Danaher Spinoff
- Veralto Corporation, the former Environmental & Applied Solutions segment of Danaher Corporation, has started trading as a publicly traded entity. Veralto is a $5 billion business focused on water and product quality, with 60% of sales generated from water quality services. The spinoff has resulted in Veralto commanding a premium valuation, although marking an interesting business to keep track of.
- 10/02/2023
|
Why Shares of Danaher Are Down Monday
- Danaher's revenues declined in the second quarter. Its spinoff, Veralto, began trading on Monday.
- 10/02/2023
|
Veralto stock to join S&P 500, Kohl's to join S&P SmallCap 600
- Danaher Corp. DHR, -0.10% spinoff Veralto Corp. VLTO.WI, +5.02% will be added to the S&P 500 before trading Monday, when it replaces DXC Technology Co. DXC, +0.59%, which in turn will move to the S&P SmallCap 600 prior to Tuesday trading. DXC Technologies will replace Ebix Inc. EBIX, -2.48% in the S&P SmallCap 600, also effective before trading Tuesday.
- 09/28/2023
|
Danaher Schedules Third Quarter 2023 Earnings Conference Call
- WASHINGTON, Sept. 26, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023 beginning at 8:00 a.m.
- 09/26/2023
|
Danaher Lowers Price Of Tuberculosis Test After Pressure Campaign
- Popular novelist and YouTuber John Green as well as international health nonprofits had been running a weeklong pressure campaign against the company.
- 09/19/2023
|
The 7 Most Undervalued Safe Stocks to Buy in September 2023
- September — widely regarded as the “worst month for the stock market” — is living up to its reputation. In fact, the S&P 500 is down 1% since August, in line with its average 1.1% monthly decline since 1928.
- 09/13/2023
|
The 3 Most Undervalued Healthcare Stocks to Buy in September 2023
- Healthcare is a sector that has underperformed the broader stock market this year. The S&P 500 Health Care Sector Index is down over 2.50% year-to-date versus a 17% gain in the benchmark S&P 500 index.
- 09/13/2023
|
The 3 Best Pharma Stocks to Buy Now: September 2023
- The pharmaceutical sector will always be a sector in constant evolution and growth. As technology advances, the companies that make life in this sector will always be applying it, as well as implementing new processes, new combinations, and new formulas, always with the aim of being able to make medicines and treatments much more effective and efficient for all of us.
- 09/08/2023
|
Here's Why You Should Steer Clear of Danaher (DHR) Stock Now
- Lower demand for COVID-related products, raw material cost inflation and foreign currency headwinds weigh on Danaher's (DHR) operations.
- 09/05/2023
|
Danaher and Veralto to Webcast Investor and Analyst Meeting
- WASHINGTON , Aug. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of Veralto's Investor and Analyst Meeting on September 6, 2023 beginning at approximately 12:00 p.m. CT. The event, which will provide a comprehensive overview of Veralto and its operating segments, will be held at Videojet's facility in Wood Dale, Illinois and hosted by Veralto President & CEO Jennifer L.
- 08/31/2023
|
Gurus' Top Stock Picks for the 2nd Quarter
- The second quarter of 2023 was characterized by moderating inflation and signs the economy remains resilient despite interest rates rising. As such, the S&P 500 gained 7.90% during the three months ended June 30, while the Dow Jones Industrial Average increased 2.40% and the Nasdaq Composite Index rallied 13.11%.
- 08/31/2023
|
When ChatGPT Misses the Mark: 3 Stocks It Got Very Wrong
- Artificial Intelligence ( AI ) has received incredible attention this year due to the public release of OpenAI's ChatGPT. Its profound capabilities have successfully captured the imaginations of a swath of audiences from technology enthusiasts and investors to social commentators.
- 08/31/2023
|
Danaher: A Lost Year
- Danaher Corporation benefited from the Covid-19 period and saw strong growth, aided by bolt-on deals and reasonable leverage. The company acquired the biopharma business from General Electric in a $21 billion deal, adding highly profitable sales. Despite strong results, the risk-reward for Danaher Corporation has deteriorated, as shares have recently recovered while 2023 performance so far has been weak.
- 08/30/2023
|
Danaher (DHR) to Acquire Abcam, Boost Life Sciences Unit
- Danaher (DHR) is set to acquire Abcam in a $5.7 billion deal, boosting its Life Sciences portfolio while solving some of the world's greatest healthcare challenges.
- 08/29/2023
|
Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings
- Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.
- 08/28/2023
|
Danaher acquires biotech supplier Abcam for $5.7B
- Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion. Danaher (NYSE:DHR) beat out rivals who were also bidding for the company including Agilent Technologies (NYSE:A), according to media reports.
- 08/28/2023
|
Medical tech firm Danaher to buy Abcam in deal valued at $5.7 bln
- Danaher Corp said on Monday it would buy smaller rival Abcam Plc in a deal valued at $5.7 billion including debt, as the medical tools supplier eyes bigger contracts by expanding its services.
- 08/28/2023
|
Danaher to Buy Abcam in $5.7 Billion Deal. Investors Don't Like the Premium.
- The industrial scientific-supplies company agrees to acquire all shares outstanding for $24.00 each.
- 08/28/2023
|
Abcam agrees to be acquired by Danaher in $5.7B deal
- Abcam Plc stock ABCM, +3.87% was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. DHR, +0.78% for $24 a share in cash in a deal that values the maker of antibodies and reagents for drug discovery efforts at about $5.7 billion including debt. The price amounts to a premium of 64 cents a share, or 2.7% over its closing price of $23.36 on Friday.
- 08/28/2023
|
Exclusive: Danaher in the lead to acquire biomedical equipment vendor Abcam-sources
- Danaher Corp is in the lead to acquire Abcam Plc , a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday.
- 08/25/2023
|
4 moments from Jim Cramer's August Monthly Meeting of the CNBC Investing Club
- Here's a sneak peek.
- 08/17/2023
|
A Billionaire's Bet: 3 Stocks Dan Loeb Thinks You Should Own
- It's not often that you read about activist investor Dan Loeb praising the chief executive officer (CEO) of a company in which Third Point Management holds a stake, but that's precisely what happened in the hedge fund's July 31 investor letter, which laid out its thoughts on some of Dan Loeb's stock picks. Third Point first took a stake in Shell (NYSE: SHEL ) in 2021, doling out $750 million in the Dutch oil giant.
- 08/10/2023
|
Buy Alert: 3 Healthcare Stocks Nearing Super Attractive Entry Points
- As a prolific cog in the economic machine, the healthcare industry has been a roller coaster ride over the past few years. With the global pandemic, economic slowdown and industry-wide disruptions in play, healthcare stocks took a major hit but are now demonstrating signs of recovery.
- 08/02/2023
|
Time To Go Defensive With These ETFs
- High-beta stocks have outperformed defensive stocks in the stock market recently, raising questions about the effectiveness of low-volatility and dividend growth investing. ROBECO's research shows that low-volatility investing can significantly improve long-term performance, particularly in market environments with increased retail investor participation. Low-risk ETFs, such as healthcare names and dividend aristocrats, offer exposure to fundamentally strong factors and tend to perform well during periods of stagflation, high inflation, and decent economic growth.
- 08/02/2023
|
7 Millionaire-Maker Healthcare Stocks to Buy Before the Window Closes
- Healthcare continues to be a major industry and economic driver around the world. According to the American Medical Association, spending on healthcare in the U.S. totals more than $4 trillion each year, which works out to nearly $13,000 per person.
- 07/27/2023
|
Is Danaher (DHR) Modestly Undervalued? An In-depth Analysis
- With a daily gain of 3.15% and Earnings Per Share (EPS) (EPS) of $8.52, Danaher Corp ( DHR , Financial) presents a compelling case for value investors. The question we aim to answer is: Is Danaher (DHR) modestly undervalued?
- 07/26/2023
|
7 Growth Stocks You Better Be Buying on Each and Every Dip
- After a dismal 2022, investors have returned to the top growth stocks to buy with great enthusiasm. We shouldn't forget the lessons from 2022, however.
- 07/25/2023
|
Danaher (DHR) Q2 Earnings Beat, Sales Decline 7.7% Y/Y
- Danaher's (DHR) Q2 earnings and revenues beat estimates. However, a decline in the sale of COVID-related products weigh on the top line.
- 07/25/2023
|
Cramer's Mad Dash on Danaher: This is a true reset
- CNBC's Jim Cramer delivers his daily Mad Dash.
- 07/25/2023
|
Danaher (DHR) Q2 Earnings and Revenues Beat Estimates
- Danaher (DHR) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.76 per share a year ago.
- 07/25/2023
|
Danaher cuts forecast for annual sales growth as biotech clients face funding crunch
- Danaher Corp on Tuesday cut its annual sales growth forecast for a second straight quarter, signaling that funding crunch in the drug development market was weighing on its biotechnology business.
- 07/25/2023
|
Danaher: A Compounding Icon At A Fair Price
- Danaher is an industry-leading serial acquirer with an iconic business system. After a boom in Danaher's sales during the pandemic, demand is now slowing as customers are facing inventory build-up and liquidity challenges. Beyond the current headwinds, Danaher's market position, balance sheet and cash flow generation remain strong and will position the company for secular growth over the long term.
- 07/25/2023
|
Will Low COVID-Testing Volumes Mar Danaher's (DHR) Q2 Earnings?
- Lower demand for COVID-19 testing, vaccine and therapeutics is expected to have hurt Danaher's (DHR) Q2 performance. Rising cost of sales might have hurt the bottom line.
- 07/17/2023
|
The 7 Most Undervalued Blue-Chip Stocks to Buy Now: June 2023
- Looking for undervalued blue-chip stocks to buy? This is a great time to be doing so.
- 06/27/2023
|
Danaher (DHR) Shares Decline 10% YTD: What's Pulling It Down?
- Lower demand for COVID-19 testing, vaccine and therapeutics within the Biotechnology and Diagnostics segments weigh on Danaher (DHR).
- 06/26/2023
|
Bear Of The Day: Danaher (DHR)
- Despite a great history of beating the number, this stock is a Zacks Rank #5 (Strong Sell) as earnings estimates have fallen.
- 06/26/2023
|
Danaher Schedules Second Quarter 2023 Earnings Conference Call
- WASHINGTON , June 20, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2023 on Tuesday, July 25, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
- 06/20/2023
|
Buy-Alert: 3 Undervalued Buffett-Style Dividend Gems I'm Buying
- This year, so far, dividend investors are dealing with underperformance as the market has shifted from value to growth stocks. This is amplified by economic growth fears. While underperformance isn't fun, weakness comes with opportunities, which is why I have aggressively added to a number of Buffett-style dividend growth stocks.
- 05/24/2023
|
Danaher: A Great Chance To Buy This Long-Term Compounder
- Thanks to its business model, Danaher has managed to reach operational excellence. Solid tailwinds will back up the company to continue its compounding path.
- 05/23/2023
|
The Great Dividend Divide: Spotting Clues From 2 Telling Companies' Payout Changes
- Earnings season has been better than feared, and we highlight two firms offering differing views on the state of the economy. There's also one falling Pharma company that (once again) delayed its Q3 results.
- 05/18/2023
|
Danaher Corporation (DHR) Bank of America Securities 2023 Healthcare Conference Transcript
- Danaher Corporation (NYSE:DHR ) Bank of America Securities 2023 Healthcare Conference May 10, 2023 1:00 PM ET Company Participants Mike Ryskin - Analyst, Bank of America Life Science Tools and Diagnostics Team Rainer Blair - Chief Executive Officer, Danaher Corporation Conference Call Participants Mike Ryskin Thank you for joining us for our next session. For those of you that don't know me, I'm Mike Ryskin on the Bank of America Life Science Tools and Diagnostics team with Co-Senior Analyst, Derik De Bruin.
- 05/14/2023
|
16 Stocks Run Circles Around Warren Buffett Over The Long Haul
- Warren Buffett held court again at Berkshire Hathaway's shareholder meeting. But his company could learn from some other S&P 500 companies.
- 05/09/2023
|
What Does Bill Gates Know That You Don't? 3 Stocks He Is Buying.
- It's been a good year for Bill Gates. According to the Bloomberg Billionaires Index , the Microsoft (NASDAQ: MSFT ) co-founder's net worth is up $15.5 billion to $125 billion.
- 05/09/2023
|
Danaher to Present at Bank of America Securities Health Care Conference
- WASHINGTON , May 3, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 10:00 a.m.
- 05/03/2023
|
China-Exposed Stocks Have Rallied, but Bargains Still Exist, Says Analyst
- Jefferies analyst Desh Peramunetilleke says cheap stocks set to benefit from China's rebound include Keysight, Qualcomm, Agilent, Danaher, and Corning.
- 05/02/2023
|
3 Innovative Water Tech Stocks to Watch in a Thirsty World
- If you're interested in investing in water tech stocks, you'd be wise to turn to Invesco. It's cornered the market on water technology companies, marketing three of the top water exchange-traded funds (ETFs) listed on U.S. stock exchanges: Invesco Water Resources ETF (NASDAQ: PHO ), Invesco S&P Global Water Index ETF (NYSEARCA: CGW ) and Invesco Global Water ETF (NASDAQ: PIO ).
- 04/27/2023
|
Investors should look at oversold stocks suffering from bloated inventories, says MAI's Grisanti
- Chris Grisanti, chief equity strategist and senior portfolio manager at MAI Capital Management, and CNBC's Mike Santoli join 'The Exchange' to discuss the home builder trade, Microsoft's decision to squash its Activision deal, and investment opportunities in the healthcare sector.
- 04/26/2023
|
Danaher (DHR) Q1 Earnings Beat, Revenues Decline 7% Y/Y
- Danaher's (DHR) Q1 earnings and revenues beat estimates. However, a decline in the sale of COVID-related products weigh on the top line.
- 04/25/2023
|
These 2 Large-Cap Laggards Are Leading Markets Lower Tuesday
- Markets fell on Tuesday amid worries about a possible recession. United Parcel Service saw drops in shipping volume that hit sales and earnings.
- 04/25/2023
|
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
- Danaher (DHR) came out with quarterly earnings of $2.36 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.76 per share a year ago.
- 04/25/2023
|
3 Healthcare Stocks With Huge Growth Potential
- It's been a rocky market for growth stocks over the past 18 months. We've seen a flurry of layoffs and spending cutbacks from leading tech companies.
- 04/24/2023
|
Danaher: A Double-Digit Earnings And Dividend Compounder
- Danaher: A Double-Digit Earnings And Dividend Compounder.
- 04/20/2023
|
7 Stocks That Hedge Funds Are Dumping Now
- While it's always important to conduct your own due diligence in the equities arena, there's great value in understanding which hedge fund stocks to avoid. Put another way, these are the stocks that hedge funds are unloading, which should inspire additional research.
- 04/17/2023
|
Can Danaher (DHR) Retain Beat Streak This Earnings Season?
- Steady demand across end markets within the Life Sciences segment is likely to have aided Danaher's (DHR) Q1 performance. However, cost and supply-chain woes might have hurt the same.
- 04/17/2023
|
7 Most Undervalued Stocks to Buy for 2023
- The stock market continues to be volatile. After a strong rally in March, all major U.S. indices have been flat so far in April, with the benchmark S&P 500 up a slight 1% since March 31.
- 04/14/2023
|
3 Stocks to Buy for Life-Changing Wealth Potential
- As an investor, finding stocks that can make you rich is as easy as making good choices and sticking by them. There are just some stocks that are going to keep winning, even if they fall back a little bit.
- 04/14/2023
|
3M, Danaher, and Kellogg Are Spinoff Stock Plays
- As the three-ring circus of rising interest rates, inflation, and bank failures plays out, corporate spinoffs and separations are worthy of investor consideration.
- 04/11/2023
|
Time to Buy Stock in These Conglomerates?
- With their extensive reach, here are three conglomerates' investors may want to consider as they are top-rated Zack stocks at the moment.
- 04/10/2023
|
My Top 10 Growth Companies To Invest In April 2023
- In this article, I will introduce you to 10 growth companies which I currently consider to be attractive. The selected picks have shown significant growth over the past years and all of them are in strong financial health.
- 04/06/2023
|
Here's Why You Should Hold on to Danaher (DHR) Stock Now
- The DBS initiatives, cost management actions and steady demand across major end markets augur well for Danaher's (DHR) growth. Handsome rewards to shareholders add to the stock's appeal.
- 03/29/2023
|
Danaher Schedules First Quarter 2023 Earnings Conference Call
- WASHINGTON , March 27, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2023 on Tuesday, April 25, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
- 03/27/2023
|
2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch
- Icon's double digit earnings growth forecast should drive its stock price. IQVIA's increased operational efficiency and earnings growth should drive its share price.
- 03/25/2023
|
18 Upcoming Dividend Increases To Finish Q1
- All these stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 11.0% and a median increase of 8.4%.
- 03/24/2023
|
Capitalizing On Chaos: My Aggressive Move To Buy More Of These 5 Dividend Growth Wonders
- Markets are in turmoil. Volatility is high and the Fed is in a tough spot. In addition to discussing macroeconomic developments, I explain my strategy and thought process when it comes to buying quality dividend growth stocks.
- 03/21/2023
|
3 Awesome Dividend Growth Stocks To Buy During A Bear Market
- Markets are in turmoil. Hence, in this article, we start with a discussion of the risks facing investors and why I believe in attractive buying opportunities this year. While I understand that investors often opt for higher-yielding investments, I will explain why investments in low-yielding dividend-growth stocks come with benefits.
- 03/14/2023
|
HTHIY vs. DHR: Which Stock Should Value Investors Buy Now?
- HTHIY vs. DHR: Which Stock Is the Better Value Option?
- 03/13/2023
|
The 7 Most Undervalued Stocks to Buy in March 2023
- The equities market continues to be incredibly volatile. Investors were optimistic following a robust rally in Jan.; all major U.S. indices are down since then.
- 03/12/2023
|
Danaher: The Secret To Successful (Dividend) Investing
- In this article, we discuss one of my favorite dividend growth stocks, which makes up for a low yield by being a consistent source of outperforming total returns. The company has a stellar high-moat M&A-driven business model with strong pricing power and often anti-cyclical customers.
- 03/06/2023
|
Danaher: Compounder Starts To Look Attractive
- Danaher has benefited from the Covid-19 period. The company has seen strong (earnings) growth, and it's positioned to maintain this.
- 03/05/2023
|
The Dividend Pyramid: Potentially Beat The Market With This 12-Stock Portfolio
- We start with a discussion of diversification theories based on the findings of a scientific article called "The Dividend Puzzle". While inexperienced investors should stick to ETFs, there's a clear case to be made for the behavioral approach, which is based on a mix of different dividend strategies.
- 03/03/2023
|
Got $300? 3 Growth Stocks to Buy That Could Double Your Money
- All three companies have shown consistent revenue and EPS growth.
- 02/21/2023
|
3 Large-Cap Biotech Stocks to Hold for the Long Haul
- Despite the sharp slide in biotech stocks during 2022, the industry is still poised for mega growth. Pandemic preparedness needs better vaccines and disease detection methods.
- 02/19/2023
|
7 Stocks to Buy for the Future of Clean Water Technology
- When many investors think about clean water stocks, the first thing that comes to mind for many investors is utility stocks. And hey, in today's volatile market, the relative safety and security that comes from owning utilities is not a bad idea.
- 02/18/2023
|
HTHIY or DHR: Which Is the Better Value Stock Right Now?
- HTHIY vs. DHR: Which Stock Is the Better Value Option?
- 02/08/2023
|
Life Storage, Newmont, Danaher stocks move on reports of M&A activity
- Yahoo Finance Live anchor Julie Hyman discusses how Life Storage, Newmont, and Danaher stocks are moving following reports of M&A activity.
- 02/06/2023
|
Catalent stock rockets 21% premarket on report of takeover interest from Danaher
- Life Sciences Company Danaher Corp. DHR, -0.31% is interested in taking over contract manufacturer Catalent Inc. CTLT, -1.04% and is willing to pay a significant premium for the company, Bloomberg reported Monday, citing people familiar with the matter. It's unclear whether Catalent is receptive, the people said, adding that a deal is not imminent.
- 02/06/2023
|
Danaher interested in buying life sciences firm Catalent- Bloomberg News
- Medical equipment maker Danaher Corp has expressed interest in taking over contract drugmaker Catalent Inc , Bloomberg News reported on Saturday, citing people familiar with the matter.
- 02/04/2023
|
Danaher: A Future-Focused Spinoff Value Play
- In September 2022, Danaher Corp. ( DHR , Financial) announced its intention to spin off its environmental and applied solutions segment into a separate publicly traded business in the fourth quarter of 2023. Called “EAS” for now until it gets an official name, the new company will include the water quality and product identification businesses.
- 01/30/2023
|
Danaher (DHR) Q4 Earnings & Revenues Beat, Increase Y/Y
- Danaher's (DHR) Q4 results benefit from strong segmental performances and organic sales growth.
- 01/24/2023
|
Danaher Corporation (DHR) Q4 2022 Earnings Call Transcript
- Danaher Corporation (NYSE:DHR ) Q4 2022 Results Conference Call January 24, 2023 8:00 AM ET Company Participants John Bedford - Vice President-Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Rachel Vatnsdal - JPMorgan Vijay Kumar - Evercore ISI Scott Davis - Melius Research Dan Brennan - Cowen and Company Patrick Donnelly - Citi Operator Good day, everyone. My name is Todd, and I will be your conference facilitator this morning.
- 01/24/2023
|
Danaher Hit After Cutting Covid-Related Revenue From Growth Reports
- The medical company's fourth-quarter earnings beat expectations, but analysts say investors are paying attention to other elements of the report.
- 01/24/2023
|
Danaher (DHR) Tops Q4 Earnings and Revenue Estimates
- Danaher (DHR) delivered earnings and revenue surprises of 16.67% and 9.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 01/24/2023
|
HTHIY vs. DHR: Which Stock Is the Better Value Option?
- HTHIY vs. DHR: Which Stock Is the Better Value Option?
- 01/23/2023
|
Ranking The Diversified Healthcare Giants
- The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles.
- 01/22/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of January 22
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 01/22/2023
|
10 Biggest Companies Reporting Earnings in the 4th Week of Jan 2023
- The fourth quarter earnings season is always the most important because it reveals the full year performance of the companies as well.
- 01/18/2023
|
Will Cost Headwinds Dampen Danaher's (DHR) Q4 Earnings?
- High raw material costs and supply-chain disruptions are likely to have hurt Danaher's (DHR) Q4 earnings. However, the top line is likely to have benefited from an expected increase in revenues at the Environmental & Applied Solutions segment.
- 01/17/2023
|
3 Stocks Ron Baron and Daniel Loeb Agree On
- Ron Baron (Trades, Portfolio) and Daniel Loeb (Trades, Portfolio) are two gurus that follow very different investing styles. While both focus on the long term, Baron's Baron Funds aims to invest in value opportunities led by quality management teams, while Loeb's Third Point LLC is focused on activist and special situations investing.
- 01/13/2023
|
My 6-Figure Market-Beating Dividend Growth Portfolio
- As requested by many, I decided to dedicate an article to my personal dividend growth portfolio, consisting of more than 90% of my net worth. I start by explaining my strategy and approach, followed by a discussion of the benefits that come with dividend (growth) investment strategies.
- 01/12/2023
|
We Have A Winner! Revisiting Danaher And Thermo Fisher
- In this article, I revisit the life sciences "picks and shovels" market leaders Danaher Corporation and Thermo Fisher Scientific Inc. I will review changes since the initial comparative piece two quarters ago.
- 01/11/2023
|
Danaher Corporation (DHR) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
- Danaher Corporation (NYSE:DHR ) 41st Annual J.P. Morgan Healthcare Conference Call January 10, 2023 4:30 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Perfect.
- 01/10/2023
|
Danaher (DHR) Provides Improved Q4 Core Revenue Growth Guidance
- Benefiting from strong growth in Cepheid's molecular diagnostics among other factors, Danaher (DHR) improves its adjusted core revenue growth guidance for the fourth quarter of 2022.
- 01/10/2023
|
Danaher sees Q4 sales increasing in ‘low-single-digit percent range'
- Danaher Corp. DHR, +1.01% on Monday said it expected fourth-quarter sales to rise in the “low-single-digit percent range,” despite what executives said was a “challenging environment” for the maker of diagnostic and life-sciences equipment. That forecast was more upbeat than FactSet's expectations for a 5% fourth-quarter sales decline to $7.71 billion.
- 01/09/2023
|
Danaher to Present at J.P. Morgan Healthcare Conference
- WASHINGTON , Jan. 3, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
- 01/03/2023
|
Why Danaher (DHR) Could Beat Earnings Estimates Again
- Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/03/2023
|
How to Find Strong Multi-Sector Conglomerates Stocks Slated for Positive Earnings Surprises
- Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- 12/30/2022
|
Final Trades: American Water, Boeing, Danaher & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 12/28/2022
|
Danaher Schedules Fourth Quarter 2022 Earnings Conference Call
- WASHINGTON , Dec. 27, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2022 on Tuesday, January 24, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
- 12/27/2022
|
10 Stocks For 2023
- The outlook for stocks in 2023 is very uncertain, with the risk of a recession. The Federal Reserve is very likely to increase interest rates throughout 2023.
- 12/23/2022
|
Grade My Trade: SMH & DHR
- The ‘Halftime Report' investment committee, Shannon Saccocia, Sarat Sethi, Joe Terranova and Jim Lebenthal, weigh in on the Danaher and semis trade.
- 12/19/2022
|
Jim Cramer recommends these 5 healthcare stocks in 2023
- Cramer said that healthcare stocks have stayed relatively steady this year because they tend to be recession-resistant stocks.
- 12/15/2022
|
Danaher (DHR) Up 14% in 6 Months: What's Driving the Stock?
- Danaher (DHR) gains from strength across its core Life Sciences segment, benefits from the DBS initiatives and acquired assets. The company's efforts to add shareholder value hold promise.
- 12/15/2022
|
Danaher: A Great Business - The Price Where I Would Buy
- The article discusses Danaher's business strategy, profitability, past and expected future growth, balance sheet quality, risks and dividend safety. Danaher is a great company that qualifies as a Peter Lynch style investment, but it has its weaknesses that are not currently being discounted by the market.
- 12/14/2022
|
Danaher Corporation (DHR) Evercore ISI HealthCONx Conference Transcript
- Danaher Corporation (NYSE:DHR ) Evercore ISI HealthCONx Conference November 30, 2022 10:30 AM ET Company Participants Rainer Blair – Chief Executive Officer Conference Call Participants Vijay Kumar – Evercore ISI Vijay Kumar Okay. Thanks, everyone, for joining us this morning.
- 11/30/2022
|
Danaher to Present at Evercore ISI HealthCONx Conference
- WASHINGTON , Nov. 22, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022 at 10:30 a.m.
- 11/22/2022
|
The 7 Most Undervalued Value Stocks to Buy Now
- Value stocks have seen a resurgence in demand during 2022. Rising interest rates increase borrowing costs, making speculative behavior less appealing.
- 11/12/2022
|
This Portfolio Manager Found A Defensive Play That Pays Off
- Calvert Equity Fund is an ESG-focused portfolio that's built to make it through tough times. The best mutual fund's steely defense, though, is also a weapon.
- 11/11/2022
|
Stock Market Sell-Off: Is Danaher Stock a Buy?
- The life sciences and diagnostics company's guidance is getting complicated.
- 10/28/2022
|
Cramer says the market got it wrong on Danaher's third quarter results
- Cramer explained why investors shouldn't have sold off shares of Danaher after the company reported earnings this week.
- 10/21/2022
|
Jim Cramer says to buy shares of Danaher on the dip
- The life sciences and medical technology company beat earnings estimates in the third quarter but narrowed its 2022 bioprocessing revenue growth forecast.
- 10/21/2022
|
Danaher's (DHR) Q3 Earnings Beat, Up Y/Y on Higher Sales
- Danaher's (DHR) Q3 results benefit from higher revenues across all segments. Organic sales rise 10%, while acquisition//divestitures boost sales by 1.5%.
- 10/20/2022
|
Danaher Corporation (DHR) Q3 2022 Earnings Call Transcript
- Danaher Corporation (NYSE:DHR ) Q3 2022 Results Conference Call October 20, 2022 8:00 AM ET Company Participants John Bedford - Vice President-Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Scott Davis - Melius Research Vijay Kumar - Evercore ISI Dan Brennan - Cowen and Company Dan Leonard - Credit Suisse Luke Sergott - Barclays Patrick Dolly - Citi Operator My name is Shelby, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2022 Earnings Results Conference Call.
- 10/20/2022
|
Danaher (DHR) Q3 Earnings and Revenues Top Estimates
- Danaher (DHR) delivered earnings and revenue surprises of 14.29% and 8.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/20/2022
|
Should You Buy Danaher (DHR) Ahead of Earnings?
- Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 10/19/2022
|
Can Danaher (DHR) Keep the Earnings Surprise Streak Alive?
- Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/18/2022
|
These 11 stocks can lead your portfolio's rebound after the S&P 500 ‘earnings recession' and a market bottom next year
- This may surprise you: Wall Street analysts expect earnings for the S&P 500 to increase 8% during 2023, despite all the buzz about a possible recession as the Federal Reserve tightens monetary policy to quell inflation.
- 10/17/2022
|
Penny Stocks & The Stock Market This Week: What To Watch Now
- Trading penny stocks right now? Here's what to watch in the stock market this week October 17, 2022 to October 21, 2022.
- 10/16/2022
|
Will Cost Woes be a Spoiler for Danaher's (DHR) Q3 Earnings?
- High raw material costs and supply chain disruptions are likely to have hurt Danaher's (DHR) Q3 earnings. However, the top line is expected to have benefited from strong segmental performances.
- 10/13/2022
|
7 Value Stocks That Are Too Cheap to Ignore
- With the global markets seeming poised to suffer a significant downturn, investors should prepare for this possibility by targeting cheap value stocks to buy. According to Investopedia.com, value-based investments refer to securities that trade at a price lower than the fundamentals imply.
- 10/09/2022
|
Key Reasons to Retain Danaher (DHR) Stock in Your Portfolio
- Healthy bioprocessing and consumables business bode well for Danaher (DHR). The company's shareholder friendly policies add to its attractiveness.
- 09/30/2022
|
Danaher's Cash Flow Profile Is Stellar
- Danaher Corporation has a stellar cash flow profile as ~70%-75% of its revenues are recurring in nature, providing ample visibility as it concerns its future financial performance. The company is worth keeping on your radar as a potential capital appreciation idea.
- 09/21/2022
|
Danaher Schedules Third Quarter 2022 Earnings Conference Call
- WASHINGTON , Sept. 20, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2022 on Thursday, October 20, 2022 beginning at 8:00 a.m.
- 09/20/2022
|
Danaher Spin-Off: What To Do With The New EAS Shares?
- On Wednesday, Danaher announced plans to spin off its Environmental & Applied Solutions Segment to create an independent company. Danaher spun off two businesses in the past.
- 09/15/2022
|
Danaher (DHR) to Spin-Off Environmental Unit, Shares Pop
- The spin-off of the Environmental & Applied Solutions segment into a new public company should help Danaher (DHR) focus on its Life Sciences and Diagnostics segments.
- 09/15/2022
|
Danaher to spin off environmental and applied solutions unit
- Medical technology firm Danaher Corp said on Wednesday it would separate its environmental & applied solutions (EAS) segment to create a publicly traded company.
- 09/14/2022
|
Danaher To Spin Off Environmental Unit
- Danaher Corp. DHR, -0.02% on Wednesday said it would spin off its Environmental & Applied Solutions segment into a separate publicly-traded company. The spin-off, expected to be completed in the fourth quarter of 2023, would help the diagnostic-tools provider become "a more focused science and technology leader committed to innovation and making a profound impact on human health," Chief Executive Rainer M.
- 09/14/2022
|
Here's who could benefit from Biden's biotech initiative, according to Oppenheimer's Jared Holz
- Oppenheimer's Jared Holz on President Biden's cancer initiative and what it means for biotech in the U.S. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Courtney Garcia, Guy Adami and Karen Finerman.
- 09/12/2022
|
Twitter, Starbucks, Oracle, Danaher, and Other Stocks to Watch This Week
- Twitter holds a shareholder vote on Tuesday over Elon Musk's acquisition. The August consumer price index will provide the latest inflation data.
- 09/11/2022
|
Investors favor stocks with stable, visible cash flows, says Bryn Mawr Trust's Jeff Mills
- Jeff Mills, CIO at Bryn Mawr Trust, joins 'The Exchange' to discuss his three "buys" and a "bail" across healthcare, energy, and tech sectors, singling out favorites: Cheniere, Merck, and Danaher.
- 09/02/2022
|
Danaher to Webcast Bioprocessing Investor and Analyst Meeting at Cytiva
- WASHINGTON , Sept. 1, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Bioprocessing Investor and Analyst Meeting at Cytiva on September 15, 2022 beginning at approximately 12:00 p.m.
- 09/01/2022
|
Danaher: Great Total Return And With Increasing Cash Flow Allowing Growth Of The Business
- Danaher Corporation's recent quarter earnings beat expected results by $0.40 on the bottom line and top-line beat by 7.3%, with an excellent gain over last year's results. Danaher's 80-month total return is fantastic, beating the Dow 80-month baseline by 248.06%, a slight increase from the last quarter.
- 08/28/2022
|
Here's Why Investors Should Retain Danaher (DHR) Stock for Now
- Danaher (DHR) is benefiting from strength in its Life Sciences segment, acquisitions and shareholder-friendly actions despite supply-chain challenges and escalating costs.
- 08/25/2022
|
Weitz Analyst Corner: Danaher Corp
- Danaher Corporation ( DHR , Financial) is a diversified science and technology company that designs, manufactures, and distributes professional, medical, industrial, and commercial products and services around the world. The company is a global leader in each of the following four businesses with operations in over 60 countries.
- 08/17/2022
|
5 Stocks Wall Street Thinks Could Soar
- The featured stocks all trade at substantial discounts to analyst price targets.
- 08/16/2022
|
Jim Cramer says these 7 Covid-era winning stocks have staying power
- The "Mad Money" host offered investors a list of Covid-era winning stocks he says are continuing to perform well on Monday's episode of the show.
- 08/08/2022
|
Final Trades: URI, DHR, EQT & CAT
- The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Steve Grasso, Karen Finerman, Jeff Mills and Courtney Garcia.
- 07/29/2022
|
7 Large-Cap Stocks to Buy on the Dip
- Following this year's sell-off, seasoned investors are increasingly hunting for large-cap stocks to buy on the dip. For instance, the S&P 500 index and Dow Jones Industrial Average have lost 185 and 13% so far in 2022.
- 07/27/2022
|
1 Conglomerate Stock You'll Be Happy You Own In 2032
- There's life after COVID-19 for Danaher, and the stock has a long pathway of growth ahead of it.
- 07/27/2022
|
Tesla, Danaher And Some Other Big Gainers From Yesterday
- U.S. stocks closed higher on Thursday, with the Nasdaq Composite jumping around 1.4%. Here is the list of some big stocks recording gains in the previous session.
- 07/22/2022
|
Danaher is on the verge of breakout as RBC analysts make a big call
- “Defensive” and “high quality” is what RBC Capital Markets called Danaher Corporation (NYSE:DHR) stock. In a note on Wednesday, RBC said that Danaher's leverage of only 1.7 times makes the stock attractive.
- 07/21/2022
|
Danaher's (DHR) Q2 Earnings & Revenues Beat, Increase Y/Y
- Danaher's (DHR) second-quarter 2022 revenues increase 7.4% year over year, driven by an impressive performance across its segments.
- 07/21/2022
|
Danaher Corporation's (DHR) CEO Rainer Blair on Q2 2022 Results - Earnings Call Transcript
- Danaher Corporation (NYSE:DHR ) Q2 2022 Earnings Conference Call July 21, 2022 8:00 AM ET Company Participants John Bedford – Vice President-Investor Relations Rainer Blair – President and Chief Executive Officer Matt McGrew – Executive Vice President and Chief Financial Officer Conference Call Participants Rainer Blair – Bank of America Vijay Kumar – Evercore ISI Scott Davis – Melius Research Dan Brennan – Cowen Jack Meehan – Nephron Rachel Vatnsdal – JPMorgan Patrick Donnelly – Citi Operator My name is Gretchen and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's Second Quarter 2022 Earnings Results Conference Call.
- 07/21/2022
|
Danaher (DHR) Beats Q2 Earnings and Revenue Estimates
- Danaher (DHR) delivered earnings and revenue surprises of 17.45% and 6.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/21/2022
|
Danaher Easily Beats Q2 Street View With Growth From Base Business; FY22 Outlook Unchanged
- Danaher Corp (NYSE: DHR) has logged Q2 FY22 adjusted EPS of $2.76, up 12% Y/Y, surpassing the estimate of $2.35. Sales increased 7.5% to $7.75 billion, with 9.5% non-GAAP core and 8.0% non-GAAP base business core revenue growth, beating the $7.32 billion estimate.
- 07/21/2022
|
Final Trades: XBI, UNH, KWEB & DHR
- The final trades of the week. With CNBC's Joe Kernen and the Fast Money traders, Tim Seymour, Jeff Mills, Bonawyn Eison and Steve Grasso.
- 07/15/2022
|
Favor companies that can continue to grow earnings, says Bryn Mawr Trust's Mills
- Jeff Mills, Bryn Mawr Trust CIO and CNBC Contributor, joins 'The Exchange' to discuss why he thinks it's time to rotate into quality growth.
- 07/12/2022
|
Will Cost Headwinds Dampen Danaher's (DHR) Q2 Earnings?
- While impressive segmental performances are expected to have aided Danaher's (DHR) Q2 performance, high costs might have impeded the bottom line.
- 07/12/2022
|
Growth stocks remain resilient in weakening economy, says Neuberger's Jason Tauber
- Jason Tauber, Neuberger Berman large cap disciplined growth and the disruptors portfolio manager, joins 'Closing Bell: Overtime' to discus his bullish case for the growth trade.
- 07/08/2022
|
HTHIY vs. DHR: Which Stock Should Value Investors Buy Now?
- HTHIY vs. DHR: Which Stock Is the Better Value Option?
- 07/07/2022
|
Danaher: A Much-Needed Pullback
- Danaher is a Dividend Challenger with 8 consecutive years of dividend growth. Shares currently yield 0.39%. Danaher is aggressive with M&A announcing 10 acquisitions totaling more than $10 B in 2021.
- 07/03/2022
|
Danaher (DHR) Exhibits Bright Prospects, Headwinds Persist
- Danaher (DHR) gains from solid demand for its products, acquired assets and shareholder-friendly policies. However, escalating costs and high debt levels remain concerns.
- 06/23/2022
|
Find businesses consumers have a harder time trading down, says FBB's Mike Bailey's
- Mike Bailey, FBB Capital Partners director of research, joins 'Power Lunch' to discuss overcoming market fears and finding opportunities in a volatile market.
- 06/22/2022
|
Danaher Schedules Second Quarter 2022 Earnings Conference Call
- WASHINGTON , June 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2022 on Thursday, July 21, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
- 06/21/2022
|
Danaher And Thermo Fisher: Buy These High-Quality Compounders At A Fair Price
- Two healthcare giants - Danaher and Thermo Fisher - are finally trading at a fair price. Over the last decades, both companies shown a great track record of excellent operations.
- 06/17/2022
|
The 7 Safest Blue-Chip Stocks You Can Buy Now
- The safest blue-chip stocks have strong catalysts bolstering their upside. As inflation soars, investing in these stocks makes more sense.
- 06/16/2022
|
MARUY or DHR: Which Is the Better Value Stock Right Now?
- MARUY vs. DHR: Which Stock Is the Better Value Option?
- 06/15/2022
|
5 High-Performing Stocks Ron Baron and Daniel Loeb Both Own
- According to the All-in-One Screener, a Premium feature of GuruFocus, five stocks that Ron Baron (Trades, Portfolio) and Daniel Loeb (Trades, Portfolio) both agree on and have outperformed the Standard & Poor's 500 index over the past three months are UnitedHealth Group Inc. ( UNH , Financial), Danaher Corp. ( DHR , Financial), TransDigm Group Inc. ( TDG , Financial), Membership Collective Group Inc. ( MCG , Financial) and ION Acquisition Corp. 3 Ltd. ( IACC , Financial).
- 06/10/2022
|
Two-minute drill: ADBE, DHR & CCI
- Ayako Yoshioka, Wealth Enhancement Group senior portfolio manager, joins 'Closing Bell: Overtime' to discuss some of her top names for investors' portfolios in the current environment.
- 06/09/2022
|
7 Blue-Chip Stocks to Buy for June 2022
- Blue-chip stocks are a smart choice during times when economic uncertainty is expected. So, here are seven blue-chip stocks to buy right now.
- 06/08/2022
|
Top Wall Street analysts are gaining more confidence in these stocks
- TipRanks analyst ranking service pinpoints Wall Street's picks for best-performing stocks, including Nvidia and Marvell.
- 06/05/2022
|
Billionaire Dan Loeb Is Betting Big on These 3 Stocks
- Dan Loeb is a veteran hedge fund manager and the CEO of Third Point. Let's take a look at his top three positions as of Q1.
- 06/02/2022
|
MS Global Franchise Portfolio's Top 5 1st-Quarter Buys
- The MS Global Franchise Portfolio (Trades, Portfolio), part of Morgan Stanley's ( MS , Financial) mutual funds, disclosed in a regulatory filing that its top five buys during the first quarter included new positions in Otis Worldwide Corp. ( OTIS , Financial) and Equifax Inc. ( EFX , Financial) and boosts to its holdings in Nike Inc. ( NKE , Financial), LVMH Moet Hennessy Louis Vuitton SE ( XPAR:MC , Financial) and Danaher Corp. ( DHR , Financial).
- 05/31/2022
|
MARUY vs. DHR: Which Stock Is the Better Value Option?
- MARUY vs. DHR: Which Stock Is the Better Value Option?
- 05/30/2022
|
Danaher: A Holding To Cover An Entire Sector
- Danaher has outperformed its benchmark for the past several decades. They successfully apply the concept of extreme focus and profit orientation in their acquisitions.
- 05/24/2022
|
Danaher: When Low-Volatility And High-Dividend Growth Meet
- In this article, I start by explaining that a low-volatility strategy is a great way to generate long-term (outperforming) wealth. Thanks to outperformance in bear markets and strong growth in bull markets, low-volatility stocks tend to be the best performers.
- 05/24/2022
|
Danaher Corporation (DHR) CEO Rainer Blair Presents at Bank of America Securities Health Care Conference (Transcript)
- Danaher Corporation (NYSE:DHR ) Bank of America Securities Health Care Conference May 11, 2022 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Derik De Bruin - Bank of America Mike Ryskin - Bank of America Derik De Bruin [Call Starts Abruptly] I'm the Senior Life Sciences and Diagnostic Tools Analyst at Bank of America with my colleague, Mike Ryskin, up here on the stage. Welcome to Bank of America's 2022 Healthcare Conference live in Las Vegas, which we're all very happy to be out of our shells.
- 05/16/2022
|
The fundamentals are in good shape for Danaher, says FBB Capital Partners' Mike Bailey
- Mike Bailey, FBB Capital Partners director of research, joins 'Power Lunch' to discuss the FAANG 'survivors,' companies that are compelling at these lower levels and more.
- 05/12/2022
|
Down 25% in 2022: Buy This High-Quality Stock on a Dip?
- Danaher's long-term prospects are being ignored because of the near-term speculation around how long the pandemic will last.
- 05/08/2022
|
Put Traders Pile on Underperforming Science and Tech Name
- Danaher Corporation (NYSE: DHR) is a global science and technology conglomerate with more than 20 operating companies.
- 05/04/2022
|
Danaher Remains Stable And Better Than Its Pre-Pandemic Level
- Danaher posted a temporary weakness on its topline growth which snowballed to its margins. It enjoys opportunities outside the pandemic which will support its topline growth.
- 04/29/2022
|
Buy 'gift horse' Danaher while it's down but leave room for other stocks, Cramer says
- "Danaher is a gift horse down here. Don't look it in the mouth, just take it," the "Mad Money" host said Friday.
- 04/22/2022
|
Buy 'gift horse' Danaher while it's down but leave room for other stocks, Cramer says
- The "Mad Money" host explained why investors should act fast to purchase Danaher stock on Friday's episode of the show.
- 04/22/2022
|
Will Danaher reverse the trend of the declining share price after Q1 results?
- Danaher Corporation (NYSE:DHR) had several weeks of downward pressure on the price. The stock appears to have consolidated in the range between $262 and $297.
- 04/21/2022
|
All You Need to Know About Danaher (DHR) Rating Upgrade to Buy
- Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 04/21/2022
|
Danaher gets lift from Covid testing, but core business is also humming
- We expect some noise around Covid testing quarter to continue as we work through China lockdowns, we think it's a distraction from Danaher's long-term story.
- 04/21/2022
|
Danaher Corporation (DHR) CEO Rainer Blair on Q1 2022 Results - Earnings Call Transcript
- Danaher Corporation (NYSE:DHR ) Q1 2022 Earnings Conference Call April 21, 2022 8:00 AM ET Company Participants John Bedford - Vice President, Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Vijay Kumar - Evercore ISI Scott Davis - Melius Research Dan Brennan - Cowen Jack Meehan - Nephron Research Patrick Donnelly - Citi Luke Sergott - Barclays Operator Good day. My name is Leo and I will be your conference facilitator this morning.
- 04/21/2022
|
Danaher (DHR) Tops Q1 Earnings and Revenue Estimates
- Danaher (DHR) delivered earnings and revenue surprises of 4.15% and 1.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/21/2022
|
Q1 Scorecard and Analyst Reports for UnitedHealth, Danaher & Wells Fargo
- Today's Research Daily features Q1 earnings season scorecard and fresh reports on UnitedHealth(UNH), Danaher (DHR), Wells Fargo (WFC) & others.
- 04/19/2022
|
Danaher Corporation's price rally nears a stop. Should you sell now?
- Danaher Corporation (NYSE:DHR) has been a stock to watch since the pandemic broke out. The company which manufactures diagnostic consumables recorded growth in revenue during the pandemic.
- 04/08/2022
|
4 Stocks With a History of Operating Income Margin Growth
- When the operating income margin continues to grow, it means a company is becoming more efficient in generating profits from its operating activities.
- 04/08/2022
|
SSUMY vs. DHR: Which Stock Is the Better Value Option?
- SSUMY vs. DHR: Which Stock Is the Better Value Option?
- 04/08/2022
|
7 Dividend Stocks to Buy Now for Boosting Payout
- In 2021, dividend stocks increased their payouts by 17%. In 2022, they're expected to average 3%.
- 03/25/2022
|
Danaher Schedules First Quarter 2022 Earnings Conference Call
- WASHINGTON, March 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2022 on Thursday, April 21, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
- 03/21/2022
|
7 Healthcare Stocks to Buy for the Long Term
- When the markets go through the massive transitions they're seeing right now, it's a great time to add quality healthcare stocks. The post 7 Healthcare Stocks to Buy for the Long Term appeared first on InvestorPlace.
- 03/21/2022
|
Investing Club: What we're watching Friday afternoon — tech rising, Danaher's big week, Boeing bump
- Boeing, Apple and Salesforce and Wells Fargo among the Club holdings that are moving Friday.
- 03/18/2022
|
8 Upcoming Dividend Increases
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List.
- 03/17/2022
|
Danaher Corp (DHR) Presents at Cowen Health Care Broker Conference (Transcript)
- Danaher Corp (DHR) Presents at Cowen Health Care Broker Conference (Transcript)
- 03/08/2022
|
Danaher: Best Healthcare Company In Inflationary Environment
- Danaher yet again delivered strong quarterly results. Revenue grew 20.5% in 4Q and 32.0% for the full year.
- 03/07/2022
|
Danaher: So Much Cash And Potential Capital Gains
- I prefer a healthy mix between high-yield and low-yield dividend growth investments in my long-term portfolio.
- 03/07/2022
|
Dividend Increases: February 19-25, 2022
- Dividend Increases: February 19-25, 2022
- 03/05/2022
|
4 Stocks to Gain From the Promising Diversified Operations Industry
- Healthy demand and improving manufacturing activities benefit players in the Zacks Diversified Operations industry. DHR, CSL, CR and GFF are stocks with strong prospects.
- 03/04/2022
|
5 ‘Strong Buy' Stocks With Dividend Hikes Expected This Week
- After years of a low interest rate environment, many investors have turned to equities, not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.
- 02/22/2022
|
This Under-the-Radar Industrial Stock Can Buy You Some Portfolio Protection
- The life sciences and diagnostics company will do well if the pandemic gets worse.
- 02/03/2022
|
Alphabet And 4 Other Stocks Sold By Insiders
- Nasdaq futures traded sharply lower this morning after Meta Platforms, Inc. (NASDAQ: FB) reported worse-than-expected Q4 EPS results and issued weak forecast. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced.
- 02/03/2022
|
Final Trades: BA, DHR, RTX & AAPL
- The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Nadine Terman and Bonawyn Eison.
- 01/28/2022
|
Cramer's Investing Club: Danaher once again delivers reliable earnings, and that's why we own the stock
- All in, this was a solid quarter from Danaher and exemplary of the type of company we believe investors must focus on in this volatile market.
- 01/27/2022
|
Danaher (DHR) Tops on Q4 Earnings, Suffers From Cost Woes
- Danaher's (DHR) Q4 earnings reflect gains from solid segmental results and higher gross and operating margins. High costs and expenses restrict margin growth.
- 01/27/2022
|
Danaher Corporation (DHR) CEO Rainer Blair on Q4 2021 Results - Earnings Call Transcript
- Danaher Corporation (DHR) CEO Rainer Blair on Q4 2021 Results - Earnings Call Transcript
- 01/27/2022
|
Danaher (DHR) Tops Q4 Earnings and Revenue Estimates
- Danaher (DHR) delivered earnings and revenue surprises of 7.60% and 4.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 01/27/2022
|
5 Must-See Earnings Charts This Week
- These five companies have been investor favorites, but can they stay in favor this earnings season?
- 01/26/2022
|
Danaher (DHR) to Report Q4 Earnings: What's in the Offing?
- Danaher (DHR) Q4 results to reflect gains from better-than-expected segmental top-line performances, mainly Diagnostics and Life Sciences. Cost inflation is likely to have been affecting margins.
- 01/24/2022
|
Down 11.8% in 4 Weeks, Here's Why Danaher (DHR) Looks Ripe for a Turnaround
- Danaher (DHR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 01/21/2022
|
ETY: A Solid Income Play
- ETY: A Solid Income Play
- 01/18/2022
|
Danaher (DHR) Q4 Sales to Exceed Guidance on Healthy Demand
- Danaher (DHR) communicates that its fourth-quarter 2021 sales performance is better than previously expected as solid demand in all three segments drives the performance.
- 01/12/2022
|
Danaher Corporation (DHR) CEO Rainer Blair Presents At JPMorgan 40th Annual Healthcare Conference (Transcript)
- Danaher Corporation (DHR) CEO Rainer Blair Presents At JPMorgan 40th Annual Healthcare Conference (Transcript)
- 01/11/2022
|
Danaher says Q4 revenue growth will exceed its guidance, stock climbs premarket
- Danaher Corp. DHR, +2.49% said Tuesday it expects fourth-quarter core revenue growth to exceed its own guidance, boosted by better-than-expected results at all three of its operating segments. The life sciences company is ow expecting revenue to grow in a high teens to low-twenties percentage range from the year-earlier period.
- 01/11/2022
|
Jim Cramer's charitable trust bought stocks during Monday's weakness. Here's why
- "When an important index like the Nasdaq trades at a three-month low, you have to at least buy something that's being thrown out," the "Mad Money" host said.
- 01/10/2022
|
Danaher To Present At J.P. Morgan Healthcare Conference
- WASHINGTON, Jan. 4, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
- 01/04/2022
|
We're buying more Danaher shares, trimming our position in this volatile credit card stock
- Following the trades, the Charitable Trust will own 175 shares of Danaher and 250 shares of Mastercard.
- 01/04/2022
|
Danaher (DHR) Gains As Market Dips: What You Should Know
- Danaher (DHR) closed the most recent trading day at $329.01, moving +0.16% from the previous trading session.
- 12/31/2021
|
Here's Why Danaher (DHR) Is a Worthy Investment Pick for 2022
- Danaher (DHR) seems a good pick for 2022. It boasts segmental opportunities, buyout-led gains, solid product offerings and a focus on innovation.
- 12/31/2021
|
5 S&P 500 Stocks That Helped the Index Score Big in 2021
- NVIDIA (NVDA), Danaher (DHR), Rockwell (ROK), Gartner (IT) and Ingersoll Rand (IR) are some of the top S&P 500 stocks that outperformed the index in 2021.
- 12/30/2021
|
DANAHER SCHEDULES FOURTH QUARTER 2021 EARNINGS CONFERENCE CALL
- WASHINGTON, Dec. 27, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2021 on Thursday, January 27, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
- 12/27/2021
|
4 Companies Growing Revenue Per Share Fast
- The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share increase at a compound annual growth rate of approximately 3.12% over the past five years. The benchmark index for the U.S. stock market closed at 4,725.79 on Thursday, up nearly 110% over the past five years through Dec. 23.
- 12/27/2021
|
My 5 Favorite Industrial Stocks for 2022
- Two blue-chip value stocks, a growth at reasonable price stock, a growth stock with upside potential, and a COVID-19 pandemic play make up a list of five stocks to buy for 2022.
- 12/27/2021
|
Envista Holdings: Not Making A Dent
- Envista Holdings: Not Making A Dent
- 12/25/2021
|
3 Reasons Growth Investors Will Love Danaher (DHR)
- Danaher (DHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 12/21/2021
|
7 of the Best ESG Stocks for 2022 to Buy Now That Will Remain Strong
- ESG stocks are increasingly attractive as capital flows into companies that care about the environment, social causes and governance. These seven stand out.
- 12/21/2021
|
Danaher (DHR) Gains As Market Dips: What You Should Know
- Danaher (DHR) closed the most recent trading day at $318.49, moving +1.11% from the previous trading session.
- 12/16/2021
|
BRRAY vs. DHR: Which Stock Is the Better Value Option?
- BRRAY vs. DHR: Which Stock Is the Better Value Option?
- 12/15/2021
|
Danaher (DHR) Gains As Market Dips: What You Should Know
- Danaher (DHR) closed the most recent trading day at $319.28, moving +0.32% from the previous trading session.
- 12/09/2021
|
Nervous About Market Volatility? 3 Safe Stocks to Buy Now
- Worried investors can fortify their portfolios with this basket of dividend and value stocks.
- 12/04/2021
|
Danaher (DHR) Dips More Than Broader Markets: What You Should Know
- In the latest trading session, Danaher (DHR) closed at $312.94, marking a -0.99% move from the previous day.
- 12/03/2021
|
Danaher Corporation's (DHR) CEO Rainer Blair Presents at Evercore ISI Annual HealthCONx Conference (Transcript)
- Danaher Corporation's (DHR) CEO Rainer Blair Presents at Evercore ISI Annual HealthCONx Conference (Transcript)
- 12/01/2021
|
Danaher: Healthcare Powerhouse
- DHR has been growing organically and through acquisitions in the past decade, and there is no sign of slowing down.
- 11/25/2021
|
Danaher To Present At Evercore ISI HealthCONx Conference
- WASHINGTON, Nov. 23, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 1:00 p.m.
- 11/23/2021
|
The Go-to Stock if the Pandemic Persists
- A look at how to insure your portfolio against a resurgence of the coronavirus pandemic.
- 11/23/2021
|
GE: Lessons From Danaher As Larry Culp Makes A Huge Move
- GE: Lessons From Danaher As Larry Culp Makes A Huge Move
- 11/10/2021
|
Danaher: Great Total Return And In The Sweet Spot With Increasing Cash Flow Allowing Growth Of The Business
- Danaher's recent quarter earnings beat expected results by $0.24 on the bottom line, and top-line beat by 23%, with an excellent gain over last year's results. Danaher's 70-month total return is fantastic, beating the Dow 70-month baseline by 265.92%, an increase from the last quarter.
- 11/07/2021
|
Danaher (DHR) is a Top-Ranked Growth Stock: Should You Buy?
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 11/05/2021
|
3 Worthy Water Stocks to Tap As Drought Becomes a New Normal
- Water has become a multi-billion dollar industry, so these three water stocks should make outstanding additions to any long-term portfolio. The post 3 Worthy Water Stocks to Tap As Drought Becomes a New Normal appeared first on InvestorPlace.
- 11/02/2021
|
4 Must-Watch Stocks in Gloomy Diversified Operations Industry
- Supply-chain, logistics and labor woes are limiting growth in the Zacks Diversified Operations industry. Despite this, DHR, CSL, RAVN and GFF are showing strength and must be on investors' watch list.
- 10/28/2021
|
Danaher (DHR) Beats on Q3 Earnings, Ups 2021 Core Sales View
- Danaher's (DHR) Q3 results reflect healthy demand for products in its three segments and a better gross margin. Pandemic-induced demand too adds to sales growth.
- 10/22/2021
|
Danaher Corporation (DHR) CEO Rainer Blair on Q3 2021 Results - Earnings Call Transcript
- Danaher Corporation (DHR) CEO Rainer Blair on Q3 2021 Results - Earnings Call Transcript
- 10/21/2021
|
Danaher (DHR) Q3 Earnings and Revenues Top Estimates
- Danaher (DHR) delivered earnings and revenue surprises of 11.68% and 3.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/21/2021
|
Danaher's Q3 Earnings Beats Street Estimates
- Danaher Corporation (NYSE: DHR) logged Q3 adjusted EPS of $2.39 up 39% Y/Y, surpassing the estimate of $2.15. Sales increased 23% to $7.2 billion, with 20.5% non-GAAP core revenue growth, beating the $7.00 billion estimate.
- 10/21/2021
|
Danaher (DHR) Earnings Expected to Grow: Should You Buy?
- Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/14/2021
|
Danaher Releases 2021 Sustainability Report; Building A Strong Foundation Of Sustainability
- WASHINGTON, Oct. 12, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company"), the global science and technology innovator, today released its 2021 Sustainability Report and highlighted the meaningful progress it has achieved in building a strong foundation of sustainability. Rainer Blair, President and CEO said, "We view sustainability as a fundamental responsibility and an increasingly important strategic priority that touches every aspect of our business.
- 10/12/2021
|
Solid U.S. Economic Fundamentals to Drive Wall Street in Q4
- We have narrowed down our search to some U.S. corporate behemoths with attractive valuation. These are: CRM, MSFT, WMT, DE, TSLA, DHR, SQ and COST.
- 10/12/2021
|
Why Danaher (DHR) Could Beat Earnings Estimates Again
- Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/07/2021
|
Danaher Corp (DHR) Sees Hammer Chart Pattern: Time to Buy?
- Danaher Corp (DHR) has been struggling lately, but the selling pressure may be coming to an end soon.
- 10/07/2021
|
Looking for Earnings Suprise? Play These 5 Stocks
- Bet big on the concept positive earnings surprise rather than earnings growth through these 5 stocks.
- 09/30/2021
|
Down 6.2% in 4 Weeks, Here's Why Danaher (DHR) Looks Ripe for a Turnaround
- Danaher (DHR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 09/29/2021
|
Here's How Much $100 Invested In Danaher 15 Years Ago Would Be Worth Today
- Danaher (NYSE:DHR) has outperformed the market over the past 90 days by 10.15%, generating a 10.28% return for its investors over the time period. Now, given this information, it may seem like price appreciation alone is the best way to have made money on this stock, that's not actually the case.
- 09/28/2021
|
Beckman Coulter's new urinalysis solution improves laboratory workflow by significantly reducing manual reviews to 4%(1) and cutting sample processing time by up to 78%(2)
- ATLANTA, Sept. 28, 2021 /PRNewswire/ -- Beckman Coulter today announced the launch of its DxU Iris Workcell at the AACC Annual Scientific Meeting & Clinical Lab Expo.
- 09/28/2021
|
Fed Gives Bond-Buy Tapering Signal Without Timeline: 5 Picks
- We have narrowed down our search to five U.S. corporate behemoths that have strong growth potential for the rest of 2021. These are: AAPL, MSFT, NVDA, DHR and COST.
- 09/23/2021
|
Danaher Schedules Third Quarter 2021 Earnings Conference Call
- WASHINGTON, Sept. 21, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2021 on Thursday, October 21, 2021 beginning at 8:00 a.m.
- 09/21/2021
|
FIW: This ETF Is Benefiting From Water Scarcity And Is Beating The S&P 500
- FIW: This ETF Is Benefiting From Water Scarcity And Is Beating The S&P 500
- 09/19/2021
|
Forget Earnings Growth, Focus on Beat With These 5 Stocks
- Inside the top-ranked stocks that can beat earnings estimates in their next releases.
- 09/16/2021
|
Danaher Announces Quarterly Dividends
- WASHINGTON, Sept. 14, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.21 per share of its common stock, payable on October 29, 2021 to holders of record on September 30, 2021.
- 09/14/2021
|
Top 5 High-Flying Low-Beta Stocks for a Volatile September
- We have narrowed down our search to five large-cap low-beta stocks that have provided double-digit returns in the past three months. These are: DHR, COST, CARR, MSI, and RSG.
- 09/13/2021
|
Danaher (DHR) Gains As Market Dips: What You Should Know
- Danaher (DHR) closed at $332.43 in the latest trading session, marking a +0.3% move from the prior day.
- 09/03/2021
|
This Medical Device Stock Has Room to Run
- Danaher Corporation (NYSE:DHR) is a global science and technology conglomerate.
- 09/02/2021
|
SCIEX Presents Industry First Multi-Capillary System for CE-SDS, the BioPhase 8800 System
- FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX presents the latest capillary electrophoresis solution, the BioPhase 8800 system, the only multi-capillary system for CE-SDS.
- 09/01/2021
|
Danaher Completes Acquisition of Aldevron
- WASHINGTON , Aug. 30, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of Aldevron. As previously announced, Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.
- 08/30/2021
|
10 Best Stocks to Buy if ESG Investing Is Your Thing
- If you're into ESG investing and are looking for stocks to buy, Morningstar created a portfolio of ESG mutual funds. Here are 10 solid ideas.
- 08/27/2021
|
7 Stocks to Buy to Cash In on Activist Investor Engine No. 1's New ETF
- Engine No. 1 forced Exxon to give the impact investment group at least two seats on its board. Here are 7 stocks to buy from its new ETF.
- 08/27/2021
|
Danaher (DHR) Stock Rise 25% in 3 Months: What's Driving It?
- Danaher (DHR), with a 25% rise in shares in the past three months, benefits from strong demand, solid product offerings and synergies from buyouts. Shareholder-friendly policies add to its appeal.
- 08/26/2021
|
Danaher To Webcast Investor And Analyst Meeting
- WASHINGTON, Aug. 25, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Investor and Analyst Meeting on September 9, 2021 beginning at 12:00 p.m. ET. The virtual event will be hosted by Rainer M.
- 08/25/2021
|
Danaher Announces Human Resources And Accounting Leadership Transition Plans
- WASHINGTON, Aug. 24, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced that, effective April 1, 2022, Georgeann F. Couchara will succeed Angela S.
- 08/24/2021
|
Danaher Announces Passing of Former President & CEO, George M. Sherman
- WASHINGTON, Aug. 20, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that George M. Sherman, the Company's President & Chief Executive Officer during the years 1990-2001, died earlier this week after an illness.
- 08/20/2021
|
These 4 Diversified Players Look Interesting Now
- This is a good time to be investing in conglomerates.
- 08/16/2021
|
Time to Focus on Danaher (DHR) for Strong Earnings Growth Potential
- If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Danaher (DHR).
- 08/13/2021
|
7 Water Stocks to Buy to Bank on Our Most Precious Resource
- As climate change forces a dramatic rethink on how we utilize our resources, these water stocks will certainly gain relevance. The post 7 Water Stocks to Buy to Bank on Our Most Precious Resource appeared first on InvestorPlace.
- 08/06/2021
|
Is Danaher a Buy in a Post-Pandemic World?
- Analyzing the investment case for buying stock in the high-flying life sciences and diagnostics company.
- 08/04/2021
|
3 Stocks With Price and Earnings Estimate Momentum
- 3 Stocks With Price and Earnings Estimate Momentum
- 07/30/2021
|
Danaher (DHR) Is Up 2.28% in One Week: What You Should Know
- Does Danaher (DHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/29/2021
|
Top Ranked Momentum Stocks to Buy for July 28th
- CROX, ISRG, MIDD, and DHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 28, 2021
- 07/28/2021
|
5 Top-Ranked Momentum Picks Using Driehaus Strategy
- DHR, CLFD, HCA, FBP, and SNBR qualified as the day's Momentum Picks Using Driehaus Strategy.
- 07/28/2021
|
Danaher (DHR) is a Top-Ranked Momentum Stock: Should You Buy?
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 07/27/2021
|
Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions
- AMERSHAM, United Kingdom, July 27, 2021 /PRNewswire/ -- An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers. The investment, already underway, includes new sites, expansion at existing factories, and is additional to previously announced investments.
- 07/27/2021
|
Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund
- The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the second quarter of the year this week.
- 07/26/2021
|
Beckman Coulter to Distribute BNP Cardiac Assay to Customers
- BREA, Calif., July 26, 2021 /PRNewswire/ -- Beckman Coulter, a global clinical diagnostics leader, today announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers.
- 07/26/2021
|
Danaher (DHR) Beats on Q2 Earnings, Ups 2021 Core Sales View
- Danaher's (DHR) Q2 results reflect strength in segmental businesses, the impact of pandemic-led tailwinds and improved margins. Projection for core sales growth, including Cytiva, increases for 2021.
- 07/22/2021
|
Danaher Corporation (DHR) CEO Rainer Blair on Q2 2021 Results - Earnings Call Transcript
- Danaher Corporation (DHR) CEO Rainer Blair on Q2 2021 Results - Earnings Call Transcript
- 07/22/2021
|
Danaher (DHR) Tops Q2 Earnings and Revenue Estimates
- Danaher (DHR) delivered earnings and revenue surprises of 20.59% and 7.83%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/22/2021
|
Danaher Posts Higher Profits, Margins On Increased Sales
- Danaher Corporation (NYSE: DHR) logged a higher profit for the second quarter as its sales grew. Adjusted EPS increased 71% Y/Y to $2.46, surpassing the estimate of $2.05.
- 07/22/2021
|
Danaher sales top analyst estimates
- Danaher sales top analyst estimates
- 07/22/2021
|
Danaher Reports Second Quarter 2021 Results
- WASHINGTON, July 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2021. All results in this release reflect only continuing operations unless otherwise noted.
- 07/22/2021
|
Here's Why Danaher Stock May Continue To Rise In The Near Term
- The stock price of Danaher, a conglomerate with products in environmental, life sciences, and diagnostics fields, has seen a 10% rise over the last twenty-one trading days, while it is up 47% over the last year, driven by positive developments for the company.
- 07/21/2021
|
Danaher: Simply Impressive
- Danaher: Simply Impressive
- 07/21/2021
|
5 Hottest Earnings Charts This Week
- These companies have earnings surprise track records and charts to envy.
- 07/20/2021
|
Here's Why You Should Invest in Water ETFs
- Water sustainability is a growing concern for many investors
- 07/20/2021
|
FSS vs. DHR: Which Stock Should Value Investors Buy Now?
- FSS vs. DHR: Which Stock Is the Better Value Option?
- 07/20/2021
|
Danaher Schedules Second Quarter 2021 Earnings Conference Call
- WASHINGTON, June 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2021 on Thursday, July 22, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
- 06/22/2021
|
5 Stocks to Ride High in Booming Diversified Operations Industry
- 5 Stocks to Ride High in Booming Diversified Operations Industry
- 06/21/2021
|
Danaher's (DHR) Aldevron Buyout to Aid Genomic Medicine
- Danaher (DHR) to gain from the Aldevron acquisition as it will increase growth opportunities in the genomic medicine field. The acquired assets will be integrated with Danaher's Life Sciences segment.
- 06/18/2021
|
Danaher (DHR) Moves 5% Higher: Will This Strength Last?
- Danaher (DHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 06/18/2021
|
SCIEX Presents New Accurate Mass Instrument, The ZenoTOF 7600 System
- FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #SCIEX--SCIEX presents the ZenoTOF 7600 system, a new accurate mass LC-MS/MS instrument that features the proprietary Zeno trap and EAD fragmentation.
- 06/17/2021
|
Time to Focus on Danaher (DHR) for Strong Earnings Growth Potential
- If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Danaher (DHR).
- 06/17/2021
|
5 Picks as Inflation is Transitory and Tapering Is Not in View
- We have narrowed down our search to five corporate bigwigs that have provided better returns than the S&P 500 Index in the past three months. These are: FDX, SHW, DHR, TGt and NVDA.
- 06/17/2021
|
Artificial Intelligence Identifies Danaher Corp Among Today's Top Buys
- The Dow Jones ticked up 20 points, the S&P 500 rose 0.1%, and the Nasdaq gained 0.2%. Make the most of today's market with the Top Buys from Q.ai's artificial intelligence.
- 06/16/2021
|
5 of the Best Stocks to Invest in for Superb Earnings Growth
- 1800 FLOWERS.COM (FLWS), Polaris (PII) & Danaher (DHR) are some of the top stocks that have striking earnings growth and positive estimate revisions at present.
- 06/15/2021
|
Danaher (DHR) is an Incredible Growth Stock: 3 Reasons Why
- Danaher (DHR) possesses solid growth attributes, which could help it handily outperform the market.
- 06/09/2021
|
Choose These 5 Low Leverage Stocks to Keep Your Portfolio Safe
- To protect one's portfolio from suffering huge losses, investors mostly choose stocks that bear low leverage. You may buy HZO, TITN, SPH, DHR and TD.
- 06/09/2021
|
Danaher (DHR) Shares Gain 11% in 3 Months: What's Driving It?
- Danaher (DHR), with an 11% rise in shares in the past three months, gains from solid product offerings, the pandemic-induced demand and focus on innovation. Inorganic activities too have been aiding.
- 06/08/2021
|
Danaher To Present At Goldman Sachs Global Healthcare Conference
- WASHINGTON, June 7, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. ET. The video will be simultaneously webcast on www.danaher.com.
- 06/07/2021
|
Danaher To Present At Jefferies Healthcare Conference
- WASHINGTON, May 27, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Jefferies Healthcare Conference on Wednesday, June 2, 2021 at 1:00 p.m. ET. The video will be simultaneously webcast on www.danaher.com.
- 05/27/2021
|
Is Danaher Stock a Buy?
- There's a lot to like about the life sciences and diagnostics company, even after the COVID-19 pandemic.
- 05/26/2021
|
Danaher: Great Total Return, Continues Strong Earnings/Revenue Growth Recovery From The COVID Pandemic
- Danaher's 65-month total return is fantastic, beating the Dow 65-month baseline by 192.88%, an increase from the last quarter. Danaher's last quarter earnings beat expected results by $0.60 on the bottom line, and top-line beat by 58.1%, with an excellent gain over last year's results.
- 05/18/2021
|
Danaher Announces Quarterly Dividends
- WASHINGTON, May 5, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.21 per share of its common stock, payable on July 30, 2021 to holders of record on June 25, 2021. In addition, the Board of Directors has approved a quarterly cash dividend of $11.875 per share of its 4.75% Series A Mandatory Convertible Preferred Stock, payable on July 15, 2021 to holders of record on June 30, 2021.
- 05/05/2021
|
Danaher To Present At Bank Of America Healthcare Conference
- WASHINGTON, May 4, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Healthcare Conference on Tuesday, May 11, 2021 at 2:00 p.m.
- 05/04/2021
|
FSS vs. DHR: Which Stock Should Value Investors Buy Now?
- FSS vs. DHR: Which Stock Is the Better Value Option?
- 05/04/2021
|
Danaher Stock: Buy at the High?
- The life sciences and diagnostic company is set up for another great year.
- 04/27/2021
|
Danaher Corporation (DHR) CEO Rainer Blair on Q1 2021 Results - Earnings Call Transcript
- Danaher Corporation (DHR) CEO Rainer Blair on Q1 2021 Results - Earnings Call Transcript
- 04/22/2021
|
Danaher's (DHR) Q1 Earnings & Revenues Surpass Estimates
- Danaher's (DHR) first-quarter 2021 revenues increase 57.9% year over year on account of impressive performance across its segments.
- 04/22/2021
|
Danaher (DHR) Q1 Earnings and Revenues Surpass Estimates
- Danaher (DHR) delivered earnings and revenue surprises of 50.90% and 0.57%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/22/2021
|
Recap: Danaher Q1 Earnings
- Shares of Danaher (NYSE:DHR) moved higher by 0.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 140.00% year over year to $2.52, which beat the estimate of $1.75.
- 04/22/2021
|
Danaher Reports First Quarter 2021 Results
- WASHINGTON, April 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2021. All results in this release reflect only continuing operations unless otherwise noted.
- 04/22/2021
|
Why Earnings Season Could Be Great for Danaher Corp (DHR)
- Danaher Corp (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 04/21/2021
|
Danaher (DHR) to Report Q1 Earnings: Is a Beat in the Cards?
- Danaher's (DHR) Q1 earnings are expected to have gained from strength across its business segments despite the coronavirus outbreak-led issues.
- 04/20/2021
|
Water ETFs: $111 Billion For Water Infrastructure
- Water ETFs: $111 Billion For Water Infrastructure
- 04/19/2021
|
Danaher (DHR) Exhibits Bright Prospects, Headwinds Remain
- Danaher (DHR) benefits from strength across its businesses, acquisitions and shareholder-friendly policies. However, rising costs and expenses remain concerning.
- 04/15/2021
|
SSUMY vs. DHR: Which Stock Should Value Investors Buy Now?
- SSUMY vs. DHR: Which Stock Is the Better Value Option?
- 04/13/2021
|
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
- Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/13/2021
|
Danaher stock rises after upbeat revenue outlook
- Shares of Danaher Corp. rose 0.7% in premarket trading Tuesday, after the maker of medical, industrial and commercial products provided an upbeat first-quarter profit outlook. The company said it expects first-quarter core revenue growth to be above the high-end of previously provided guidance.
- 04/13/2021
|
Danaher Provides Update On First Quarter 2021 Financial Performance
- WASHINGTON, April 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company's previously communicated guidance range. For the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%.
- 04/13/2021
|
Top Stocks To Buy Today As April Keeps Up The Strength
- Although Friday is set for mixed trading, the indices are set to close the week with solid gains as the S&P continues hovering around a record high. Meanwhile, Q.ai's deep learning algorithms have brought you today's top buys.
- 04/09/2021
|
7 Safe Stocks to Buy for Uncertain Times
- It's certainly a hot market, but sector rotation and consolidation in select sectors means that safe stocks are now the most appealing. The post 7 Safe Stocks to Buy for Uncertain Times appeared first on InvestorPlace.
- 04/09/2021
|
Covid Vaccines Are Ramping Up. That Could Fuel Gains For Danaher.
- With Covid vaccine manufacturing on the upswing, shares of Danaher could gain 20%, according to Citigroup.
- 04/08/2021
|
Abercrombie, Pfizer, Teva and More of Wednesday Afternoon Analyst Calls
- With the trading day approaching halfway over, the broad markets were trading marginally positive.
- 04/07/2021
|
First Trust Water ETF: Because The World Is Running Out Of Potable Water
- First Trust Water ETF: Because The World Is Running Out Of Potable Water
- 04/02/2021
|
7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic
- Covid-19 has put healthcare stocks in the limelight. These seven companies should be on your radar for the next pandemic.
- 04/01/2021
|
Danaher Schedules First Quarter 2021 Earnings Conference Call
- WASHINGTON, March 25, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2021 on Thursday, April 22, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
- 03/25/2021
|
Beckman Coulter's SARS-CoV-2 IgG II antibody test receives Emergency Use Authorization from the FDA
- BREA, Calif., March 23, 2021 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced that its Access SARS-CoV-2 IgG II antibody assay received U.S. Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration.
- 03/23/2021
|
Dividend Challenger Highlights: Week Of March 21
- A weekly summary of dividend activity for Dividend Challengers. Companies which changed their dividends.
- 03/21/2021
|
Danaher: Great Total Return And Last Quarter Revenues Had Strong Increases
- Danaher's 63-month total return is fantastic, beating the Dow 63-month baseline by 138.09%. Last quarter's earnings beat expected results by $0.25 on the bottom line and top line beat with a good gain over last year's results.
- 03/21/2021
|
4 Upcoming Dividend Increases
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List.
- 03/18/2021
|
Beckman Coulter Offers $4/High-throughput Antigen Test to Support U.S. Government Initiative to Expand COVID-19 Testing
- BREA, Calif., March 18, 2021 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced their commitment to support the U.S. government's plan to invest more than $12 billion to expand COVID-19 testing with their high-throughput, high-quality lab antigen test, Access SARS-CoV-2 Ag,* ideal for mass screening testing.
- 03/18/2021
|
Upcoming Ex-Dividend Dates: March 16-29, 2021
- In this article series, we provide a summary of upcoming ex-dividend dates.
- 03/15/2021
|
Danaher Corporation (DHR) Management Presents at Barclays Global Healthcare Conference (Transcript)
- Danaher Corporation (DHR) Management Presents at Barclays Global Healthcare Conference (Transcript)
- 03/11/2021
|
7 Stocks With Significant Insider Buying
- There are many reasons an insider might sell. But there is only one reason for insider buying; insiders think the stock will trade higher.
- 03/09/2021
|
Danaher Corporation (DHR) CEO Rainer Blair Presents at Cowen 41st Annual Health Care Conference (Transcript)
- Danaher Corporation (DHR) CEO Rainer Blair Presents at Cowen 41st Annual Health Care Conference (Transcript)
- 03/01/2021
|
February Ends in Green Amid Extreme Volatility: 5 Top Picks
- We have narrowed down our search to five corporate behemoths that suffered a blow in last month's turmoil. These are AAPL, MSFT, FB, ABT and DHR.
- 03/01/2021
|
Dividend Increases: February 20-26, 2021
- Dividend Increases: February 20-26, 2021
- 02/28/2021
|
Why Is Danaher (DHR) Down 3.9% Since Last Earnings Report?
- Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
- 02/27/2021
|
Danaher (DHR) to Gain on Segmental Strength, Inorganic Actions
- Danaher (DHR) is poised to benefit from growth opportunities within its segments. Also, gains from acquired assets and divestments as well as shareholder-friendly policies are likely to favor.
- 02/26/2021
|
Danaher To Present At Cowen Healthcare Conference
- WASHINGTON, Feb. 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Cowen Healthcare Conference on Monday, March 1, 2021 at 11:40 a.m. ET. The video will be simultaneously webcast on www....
- 02/22/2021
|
4 Worthy Stocks From Flourishing Diversified Operations Industry
- Players in the Zacks Diversified Operations industry are leveraging the pandemic-induced demand in the medical equipment and personal safety products markets. Also, strengthening businesses in markets like defense and industrial manufacturing are boons.
- 02/12/2021
|
Lean Principles and Value Investing: An Interesting Parallelism
- Introduction: What is lean manufacturing?
- 02/06/2021
|
Is Danaher Stock a Buy?
- The key to the stock's prospects will be to continue its earnings trajectory in a post-COVID-19 world.
- 02/04/2021
|
Danaher Corporation (DHR) CEO Rainer Blair on Q4 2020 Results - Earnings Call Transcript
- Danaher Corporation (DHR) CEO Rainer Blair on Q4 2020 Results - Earnings Call Transcript
- 01/28/2021
|
Danaher (DHR) Q4 Earnings Beat Estimates, Sales View Solid
- Danaher's (DHR) Q4 results reflect strength in Diagnostics, Life Sciences, and Environmental & Applied Solutions segments as well as growth in margins. Core sales growth projections are impressive.
- 01/28/2021
|
Danaher (DHR) Q4 Earnings and Revenues Surpass Estimates
- Danaher (DHR) delivered earnings and revenue surprises of 13.04% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 01/28/2021
|
Should You Buy Danaher (DHR) Ahead of Earnings?
- Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 01/27/2021
|
Top 6 Stocks Poised to Beat on Q4 Earnings Tomorrow
- Six stocks are set to beat fourth-quarter earnings estimates tomorrow. These are: DHR, DOV, OLN, PHM, HTH, NATI.
- 01/27/2021
|
5 Incredible Perfect Earnings Charts
- It's not easy to beat every quarter on earnings for five years, including during a global pandemic. These companies have done it.
- 01/26/2021
|
Will Danaher (DHR) Keep Its Earnings Streak Alive in Q4?
- Danaher (DHR) Q4 results to reflect benefits from solid Diagnostics and Life Sciences demand. Also, positive impacts of acquired assets and foreign currency translations are likely to have aided.
- 01/26/2021
|
How Danaher Created An Enduring Competitive Advantage
- The Danaher Corporation uses a continuous improvement strategy called the Danaher Business System. After starting as a Lean Manufacturing practice, it evolved and expanded into a system that affects every aspect of the company's operations and business.
- 01/14/2021
|
Danaher Corporation (DHR) CEO Rainer Blair Presents at J.P. Morgan Healthcare Conference Call Transcript
- Danaher Corporation (DHR) CEO Rainer Blair Presents at J.P. Morgan Healthcare Conference Call Transcript
- 01/13/2021
|
Danaher CEO To Comment On Financial Performance
- WASHINGTON, Jan. 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment today on the Company's fourth quarter 2020 performance in a presentation at the J.P. Morgan Healthcare...
- 01/13/2021
|
7 Top Corporate Behemoths With Immense Upside Left in 2021
- We have narrowed down our search to seven corporate behemoths that have strong growth potential in 2021. These are: TSLA, SQ, NVDA, FB, AVGO, DHR and QCOM.
- 01/12/2021
|
Danaher Schedules Fourth Quarter 2020 Earnings Conference Call
- WASHINGTON, Jan. 7, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2020 on Thursday, January 28, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour. The call and an accompanying...
- 01/07/2021
|
Wall Street Defeats Pandemic: Bulls Set to Roar in 2021
- We have selected eight stocks that have strong strong potential for 2021 and beyond. These are: DE, MU, GM, TSLA, FDX, NVDA, DHR and GOOGL.
- 01/04/2021
|
ETFs: 5 Funds For Investing In Water, A Vital Resource
- Water doesn't typically get the same focus that I put on other utilities like electric and gas companies. Though, that doesn't mean that investing in water ETFs doesn't have its own merits; it certainly does as global demand rises, yet supply doesn't go up.
- 12/26/2020
|
5 Must-Buy Corporate Giants as Major Indexes Hit Record High
- We have narrowed down our search to five corporate behemoths that have popped more than 30% year to date. These are: NVDA, DHR, UPS, MSFT and AVGO.
- 12/18/2020
|
Mohnish Pabrai Shares Insights on Identifying 10 to 100-Baggers - Part 1
- Renowned value investor Mohnish Pabrai (Trades, Portfolio) recently gave a lecture for the Fall 2020 Value Investing Course at Peking University's Guanghua School of Management. During the lecture, Pabrai shared his insights on how to spot 10 to 100-baggers, which he calls the holy grail of investing.
- 12/06/2020
|
Why Management Matters: The 3 Best-Run Industrial Companies in America
- Three well-run companies and what investors can take away from their outperformance in the past decade.
- 12/04/2020
|
Danaher Corporation (DHR) CEO Rainer Blair Presents at Evercore ISI 3rd Annual HealthCONx Brokers Conference (Transcript)
- Danaher Corporation (DHR) CEO Rainer Blair Presents at Evercore ISI 3rd Annual HealthCONx Brokers Conference (Transcript)
- 12/01/2020
|
Notable Insider Buys in the Past Week: Biglari, Coty, Danaher, Foot Locker And More
- Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there was before and after the elections and as the pandemic worsens.
- 11/28/2020
|
RBC Downgrades Danaher, Says Defensive Portfolio 'Less Compelling To Own'
- Science and technology company Danaher Corporation (NYSE: DHR) boasts a high-quality and defensive portfolio that has become "less compelling to own" ahead of a cyclical recovery into 2021, according to RBC Capital Markets. The Analyst: Deane Dray downgraded Danaher from Outperform to Sector Perform with a price target lowered from $273 to $234.
- 11/25/2020
|
Danaher (DHR) Down 3.5% Since Last Earnings Report: Can It Rebound?
- Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
- 11/21/2020
|
Is Danaher Stock a Buy?
- Analyzing the investment case for one of the big winners from the coronavirus pandemic.
- 11/20/2020
|
Danaher To Present At Wolfe Research Healthcare Conference
- WASHINGTON, Nov. 16, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Wolfe Research Healthcare Conference on Thursday, November 19, 2020 at 12:00 p.m. ET. The audio will be...
- 11/16/2020
|
Top 10 Stocks Billionaire Ray Dalio Just Bought
- In this article we present the list of Top 10 Stocks Billionaire Ray Dalio Just Bought. Click to skip ahead and see the Top 5 Stocks Billionaire Ray Dalio Just Bought .
- 11/15/2020
|
These 4 Top Stocks Have Surpassed Management's Highest Expectations
- The recent outperformances of these very different companies reveal much about which investment themes are working at this point in 2020.
- 11/04/2020
|
7 5G Stocks to Buy for the Future of the Machine Internet
- The 2020s will see machine data become intelligence, intelligence become automation, and automation spread from factories to cities and your wrist. The post 7 5G Stocks to Buy for the Future of the Machine Internet appeared first on InvestorPlace.
- 11/03/2020
|
Danaher Is One of the Big Winners From COVID-19
- The company's diagnostic tests and life sciences research tools are being extensively used in the fight against the pandemic.
- 10/30/2020
|
Danaher: Great Gain In Revenue From Pandemic
- Danaher's last quarter earnings beat expected results on the bottom and top line and with a good gain over last year's results when the dividend was increased to 6%. Danaher's three-year forward CAGR of 13% is good and will give you long-term growth with increasing demand for more medical and industrial products as the economy and population increases.
- 10/30/2020
|
3 Tech Growth Stocks to Consider
- Investors focused on tech growth stocks may want to consider the following companies, as their quarterly revenue and net income have had strong growth on a year-over-year basis.
- 10/28/2020
|
Buy Danaher Stock and Let It Work For You
- DHR stock is at the heart of the Machine Internet, using sensors and networks to transform how other things are made. The post Buy Danaher Stock and Let It Work For You appeared first on InvestorPlace.
- 10/27/2020
|
De omzet van Danaher Corp stijgt tot £4,49 miljard in Q3 | Invezz
- De omzet van Danaher Corp stijgt tot £4,49 miljard in het fiscale derde kwartaal. Het nettoresultaat van het Amerikaanse bedrijf bedroeg £674,63 miljoen.
- 10/22/2020
|
Los ingresos de Danaher Corp ascienden a 4.,490 millones de libras en el tercer trimestre fiscal | Invezz
- Danaher Corp (NYSE: DHR) dijo el jueves que sus ventas y ganancias en el tercer trimestre fiscal fueron mejores de lo esperado. Las acciones de la compañía subieron más del 3% en el mercado abierto. Danaher Corp ha ganado cerca del 100% en el mercado de valores desde finales de marzo. ¿Interesado en invertir en el mercado de valores online? Aquí hay una guía simple para comenzar. Resultados financieros del tercer trimestre de Danaher Corp frente a estimaciones de analistas Danaher Corp. dijo que sus ingresos netos en el tercer trimestre fueron de 674,63 millones de libras esterlinas (antes de
- 10/22/2020
|
Danaher Corp’s revenue climbs to £4.49 billion in the fiscal third quarter.
- Danaher Corp’s revenue climbs to £4.49 billion in the fiscal third quarter. The U.S. firm's net income in the third quarter printed at £674.63 million.
- 10/22/2020
|
Danaher Corporation (DHR) CEO Rainer Blair on Q3 2020 Results - Earnings Call Transcript
- Danaher Corporation (NYSE:DHR) Q3 2020 Earnings Conference Call October 22, 2020 08:00 ET Company Participants Matt Gugino - Vice President, Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Tycho Peterson - JPMorgan Derik de Bruin - Bank of America Scott Davis - Melius Research Doug Schenkel - Cowen Vijay Kumar - Evercore ISI Dan Brennan - UBS Steve Beuchaw - Wolfe Research Presentation Operator Good morning.
- 10/22/2020
|
Global Capillary Electrophoresis Market 2020-2024- Featuring Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corp., Among Others
- The Global Capillary Electrophoresis Market will grow by $ 300.97 mn during 2020-2024
- 10/22/2020
|
COVID-19 Impact and Recovery Analysis |Laboratory Equipment Services Market Procurement Intelligence Report Forecasts Spend Growth of over USD 24 Billion
- Laboratory Equipment Services Market is poised to experience spend growth of more than USD 24 billion between 2020-2024 at a CAGR of over 6.23%.
- 10/18/2020
|
Hemoglobin Testing Market | Growing Incidence of Diabetes Worldwide to Boost Market Growth | Technavio
- The Global Hemoglobin Testing Market will grow by $ 612.82 mn during 2020-2024
- 10/16/2020
|
Global Polymerase Chain Reaction (PCR) Market Trajectory & Analytics Report 2020 with Profiles of 40+ Key Players - ResearchAndMarkets.com
|
Oncology Molecular Diagnostics - Global $3.6 Billion Market Trajectory & Analytics to 2027 - ResearchAndMarkets.com
|
Your portfolio is not as diversified as you think, unless you are utilizing this powerful strategy
- There’s an overlooked asset class that can uncover opportunities for you while cutting risk.
- 10/13/2020
|
DNA Sequencing Market to Reach $ 12.5 bn by 2024, Agilent Technologies Inc., BGI Genomics Co. Ltd., and Thermo Fisher Scientific Inc., Emerge as Key Contributors to Growth | Technavio
- The Global DNA Sequencing Market will grow by USD 12.5 bn during 2020-2024
- 10/13/2020
|
Cypress Capital Group Sells 340 Shares of Danaher Co. (NYSE:DHR)
- Cypress Capital Group reduced its stake in shares of Danaher Co. (NYSE:DHR) by 4.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,103 shares of the conglomerate’s stock after selling 340 shares during the quarter. Cypress Capital Group’s holdings in Danaher were worth […]
- 10/09/2020
|
TOC Analyzer Market to Reach $ 327.51 Mn by 2024, Danaher Corp. and Endress+Hauser Management AG Emerge as Key Contributors to Growth | Technavio
- The Global TOC Analyzer Market will grow by USD 327.51 mn during 2020-2024
- 10/09/2020
|
Servo System Market Growth 2020 Global Industry Size, Analysis, Share, Trends, Market Demand, Growth, Opportunities and Covid-19 Impact Analysis on Forecast 2025
- Oct 08, 2020 (The Expresswire) --
Global "Servo System Market" 2020 report spins around the critical creators of the Servo System market universally with...
- 10/08/2020
|
Breast Biopsy Device Market| Growing Prevalence of Breast Cancer Cases to Boost the Market Growth | Technavio
- The Global Breast Biopsy Devices Market will grow by USD 504.94 mn during 2020-2024
- 10/08/2020
|
Danaher Schedules Third Quarter 2020 Earnings Conference Call
- WASHINGTON, Oct. 7, 2020 /PRNewswire via COMTEX/ --
WASHINGTON, Oct. 7, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it will...
- 10/07/2020
|
After Yesterday's Rally of 2.07% Shares Could Potentially Pullback
- Oct 07, 2020 (SmarTrend(R) News Watch via COMTEX) --
Danaher Corp (NYSE:DHR) traded in a range yesterday that spanned from a low of $219.36 to a high of...
- 10/07/2020
|
Danaher Corp Rises 2.07% on Heavy Volume: Watch For Potential Pullback
- Oct 07, 2020 (SmarTrend(R) News Watch via COMTEX) --
Danaher Corp (NYSE:DHR) traded in a range yesterday that spanned from a low of $219.36 to a high of...
- 10/07/2020
|
Health Sensors Market 2020 impact of COVID-19 on Global Industry Demand, Share, Top Players, Industry Size, Future Growth by 2025 Research Reports World
- Oct 07, 2020 (The Expresswire) --
Global "Health Sensors Market" 2020 research report includes an outline of the business with industrial chain structure,...
- 10/07/2020
|
COVID-19 Impact and Recovery Analysis | Laboratory Equipment Services Market Procurement Intelligence Report Forecasts Spend Growth of Over USD 24 Billion | SpendEdge
- Global Laboratory Equipment Services Market is poised to experience spend growth of more than USD 24 billion between 2020-2024 at a CAGR of over 6.23%
- 10/07/2020
|
Danaher Announces Redemption Of Senior Notes
- WASHINGTON, Oct. 6, 2020 /PRNewswire via COMTEX/ --
WASHINGTON, Oct. 6, 2020 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today that...
- 10/06/2020
|
Cell Isolation Market to reach USD 9.47 bn by 2024, Agilent Technologies Inc. and Becton, Dickinson and Co. emerge as Key Contributors to Growth| Technavio
- The Global Cell Isolation Market will grow by USD 9.47 bn during 2020-2024
- 10/06/2020
|
Uptrend Call Working As Danaher Corp Stock Rises 57.7% (DHR)
- Oct 05, 2020 (SmarTrend(R) Spotlight via COMTEX) --
SmarTrend identified an Uptrend for Danaher Corp (NYSE:DHR) on March 27th, 2020 at $137.76. In...
- 10/05/2020
|
Charting a successful technical test, S&P 500 rallies from major support
- U.S. stocks are firmly higher early Monday, rising as a constructive October start remains underway. Against this backdrop, the S&P 500 is challenging...
- 10/05/2020
|
Clinical Mass Spectrometry Market by End-User (Healthcare Facilities and Pharma and Biotech Companies and Research Labs and Institutes) and Geography (Asia, Europe, North America, and ROW) | COVID-19 Impact Analysis
- The Global Clinical Mass Spectrometry Market will grow by USD 1.70 bn during 2020-2024
- 10/03/2020
|
Danaher Demands A Price For Its Quality (NYSE:DHR)
- Danaher is a high-quality business. The business model yields steady growth and is largely protected against economic shocks.
- 10/01/2020
|
Danaher Announces Pricing Of Senior Notes Offering
- WASHINGTON, Sept. 29, 2020 /PRNewswire via COMTEX/ --
WASHINGTON, Sept. 29, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today...
- 09/30/2020
|
Global Dental Cements Market Trajectory & Analytics, 2020-2027 - ResearchAndMarkets.com
|
Surgical Smoke Evacuation Systems Market- Roadmap for Recovery from COVID-19 | Increasing Number of Surgical Procedures to Boost Market Growth | Technavio
- The Global Surgical Smoke Evacuation Systems Market will grow by USD 32.89 mn during 2020-2024
- 09/28/2020
|
Correction Notice To Press Release Regarding Dividend Amount
- WASHINGTON, Sept. 25, 2020 /PRNewswire via COMTEX/ --
WASHINGTON, Sept. 25, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced...
- 09/25/2020
|
Insights on the Immunoprotein Diagnostic Testing Global Market to 2027 - Key Trends and Drivers - ResearchAndMarkets.com
|
Molecular Microplate Readers and Washers Market 2020-2024: Forecasting Strategy to Undergo A Paradigm Shift from Crisis to New Normal during COVID-19 Pandemic | Technavio
- The Global Molecular Microplate Readers and Washers Market will grow by USD 270.80 mn during 2020-2024
- 09/24/2020
|
Laboratory Equipment Services Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
- The Laboratory Equipment Services market will register an incremental spend of about $24 billion, growing at a CAGR of 6.23%.
- 09/21/2020
|
COVID-19 Recovery Analysis: UV Lamp Market | The Declining Manufacturing Costs to Boost the Market Growth | Technavio
- The Global UV Lamp Market will grow by $ 820.63 mn during 2020-2024
- 09/18/2020
|
Chromatography Market- Roadmap for Recovery from COVID-19 | Growing Demand For Portable Analytical Systems to boost the Market Growth | Technavio
- The Global Chromatography Market will grow by $ 4.13 bn during 2020-2024
- 09/17/2020
|
Respiratory Syncytial Virus Diagnostics Market- Roadmap for Recovery from COVID-19 | Increase in Product Launches to boost the Market Growth | Technavio
- The Global Respiratory Syncytial Virus (RSV) Diagnostics Market will grow by USD 585.17 mn during 2020-2024
- 09/16/2020
|
Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q2 2020 Update
- Wallace Weitz's 13F portfolio value increased from $1.88B to $2.01B this quarter. The number of positions decreased from 69 to 65.
- 09/15/2020
|
Spectrophotometer Market: COVID-19 Business Continuity Plan | Evolving Opportunities With Agilent Technologies Inc. and Avantor Inc. | Technavio
- The Global Spectrophotometer Market will grow by $ 869.24 mn during 2020-2024
- 09/15/2020
|
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
- Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71.
- 09/11/2020
|
A Quarterly Hiccup At Donaldson May Be An Opportunity For Long-Term Investors
- Donaldson disappointed the Street with its fourth quarter numbers, but the underlying performance wasn't that bad, as the aftermarket business held up well and the company invests in long-term growth.
- 09/08/2020
|
Tracking Dan Loeb's Third Point Portfolio - Q2 2020 Update
- Dan Loeb's 13F portfolio value increased from $6.27B to $7.30B this quarter. The number of positions increased from 30 to 36.
- 08/28/2020
|
Colfax's Rate Of Recovery Will Demonstrate The Strength Of Newly Transformed Portfolio
- Colfax’s exit from volatile oil and gas business and entry into more defensive medical technology business has put it in a good position to weather the current coronavirus slowdown.
- 08/28/2020
|
Global Water Quality Monitoring Devices Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com
|
The Dental Lab Market - Global Drivers, Restraints, Opportunities, Trends and Forecast to 2026 - ResearchAndMarkets.com
|
COVID-19 Pandemic Impact on Global Automated Microbiology Market 2020-2024 | Technavio
- The Global Automated Microbiology Market will grow by USD 744.20 mn during 2020-2024
- 08/26/2020
|
Tracking David Einhorn's Portfolio - Q2 2020 Update
- David Einhorn's 13F stock portfolio value increased from $702M to $922M this quarter. Greenlight added Vaneck Gold Miners ETF and Atlas Air Worldwide while dropping Altice USA and Adient plc.
- 08/25/2020
|
COVID-19 Pandemic Impact on Global Oscilloscope Market 2020-2024 | Technavio
- The Global Oscilloscope Market will grow by USD 213.19 mn during 2020-2024
- 08/25/2020
|
Analysis on Impact of COVID-19: Chromatography Resins Market 2020-2024 | Increasing R&D In Biopharmaceuticals to Boost the Market Growth | Technavio
- The Global Chromatography Resins Market will grow by USD 1.17 bn during 2020-2024
- 08/24/2020
|
How To Use Momentum Statistics To Improve Trading Results
- Using actual trading data and momentum statistics can help break down the supply/balance in a stock. Ignoring exceptionally strong or weak momentum characteristics can often become a money losing proposition.
- 08/23/2020
|
3 Safe High-Yield Blue-Chip Bargains Retirees Will Love
- The speculative mania in certain stocks continues, with Tesla now the 9th most valuable company in America, trading at 88X 2022 earnings estimates.
- 08/23/2020
|
The Good Business Portfolio: 2020 2nd Quarter Earnings And Performance Review
- The 23 businesses comprise 99% of the portfolio with the other 1% in cash, and the average total return over the Dow average for the 56-month test period is 30.18%.
- 08/23/2020
|
COVID-19 Impacts: Global Metabolomics Market will Accelerate at a CAGR of over 12% through 2020-2024 | Increased Adoption in the Field of Precision Medicine to Boost Growth | Technavio
- The Global Metabolomics Market will grow by $ 1.54 bn during 2020-2024
- 08/22/2020
|
3M Co. stock rises Friday, still underperforms market
- Shares of 3M Co. inched 0.13% higher to $161.71 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...
- 08/21/2020
|
3M Co. stock falls Thursday, underperforms market
- Shares of 3M Co. slipped 0.61% to $162.97 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...
- 08/20/2020
|
Quidel: An Impressive Growth Story For The Long Term
- Quidel is a high growth in vitro diagnostics company which is continuously developing new products. The company's total revenue in the second quarter increased 86% YoY driven by COVID-19 tests.
- 08/19/2020
|
Charting a pulling-teeth breakout attempt: S&P 500, Nasdaq challenge record territory
- Technically speaking, the S&P 500 and Nasdaq Composite have registered nominal record highs this week, though a pulling-teeth breakout attempt remains...
- 08/18/2020
|
The Danaher (NYSE:DHR) Share Price Has Gained 149%, So Why Not Pay It Some Attention?
- The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
- 08/18/2020
|
Crane to Benefit From Acquisitions Amid Pandemic Scares
- Crane (CR) is likely to benefit from the exposure in diverse end-markets, acquired assets and repositioning initiatives. However, the coronavirus outbreak-led market downturn remains concerning.
- 08/18/2020
|
Griffon Prices 8M Underwritten Public Common Share Offering
- Griffon (GFF) prices 8-million common share offering. Proceeds raised will be used for debt reduction and other corporate purposes.
- 08/14/2020
|
Tracking Charles Akre's Akre Capital Management Portfolio - Q2 2020 Update
- Chuck Akre’s portfolio value increased from $10.29B to $13.27B this quarter. Akre Capital Management increased CoStar Group and ANSYS, Inc.
- 08/13/2020
|
3M Co. stock outperforms market on strong trading day
- Shares of 3M Co. advanced 1.20% to $163.38 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...
- 08/11/2020
|
Charting the approach of record highs, S&P 500 rises amid market rotation
- Technically speaking, the U.S. benchmarks’ already-bullish backdrop has strengthened amid rotational August price action, writes Michael Ashbaugh.
- 08/11/2020
|
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2020 Update
- Fisher’s 13F portfolio value increased from $80.64B to $102.5B in Q2 2020. They increased PayPal, Walt Disney, NextEra Energy, UnitedHealth, 3M Company, Intuitive Surgical, Abbott Labs, Starbucks, and Thermo Fisher Scientific during the quarter.
- 08/11/2020
|
Global Metabolomics Market 2020-2024: Projected to Grow by $1.54 Billion Over the Forecast Period - ResearchAndMarkets.com
|
3M Co. stock outperforms market on strong trading day
- Shares of 3M Co. advanced 1.96% to $161.44 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...
- 08/10/2020
|
Ariel Investments' John Rogers Shares Insight About Stocks, Racial Relations
- John Rogers, the first Black founder of a mutual fund complex, offers advice about investments and what this summer of agitation is telling Americans.
- 08/10/2020
|
Laboratory Analytical Instruments and Consumables Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Rising Applications of Analytical Instruments to Boost Market Growth | Technavio
- The Global Laboratory Analytical Instruments and Consumables Market will grow by USD 13.81 bn during 2020-2024
- 08/10/2020
|
COVID-19 Impacts: Scanning Electron Microscope Market Will Accelerate at a CAGR of almost 8% through 2020-2024 | Increasing Focus on Nanotechnology to Boost Growth | Technavio
|
Automated Test Equipment Market Highlights the Impact of COVID-19 2020-2024 | Augmented Production of Electronic Goods to Boost Market Growth | Technavio
- The Global Automated Test Equipment Market will grow by USD 1.47 bn during 2020-2024
- 08/08/2020
|
3M Co. stock outperforms market on strong trading day
- Shares of 3M Co. advanced 1.49% to $158.33 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...
- 08/07/2020
|
5 Health Care Companies Outperforming the Market
- UnitedHealth on the list Continue reading...
- 08/07/2020
|
Insights on the Global Antimicrobial Susceptibility Testing Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio
- The Global Antimicrobial Susceptibility Testing Market will grow by USD 900.75 mn during 2020-2024
- 08/07/2020
|
3M Co. stock rises Thursday, still underperforms market
- Shares of 3M Co. inched 0.42% higher to $156.00 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...
- 08/06/2020
|
3M Co. stock outperforms competitors on strong trading day
- Shares of 3M Co. advanced 2.74% to $155.35 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
- 08/05/2020
|
3M Co. stock rises Tuesday, outperforms market
- Shares of 3M Co. inched 0.53% higher to $151.21 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...
- 08/04/2020
|
Charting a solid August start: S&P 500, Nasdaq stage latest summer breakouts
- Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish amid a solid August start, writes Michael Ashbaugh.
- 08/04/2020
|
COVID-19 Impacts: Biotechnology Reagents Market Will Accelerate at a CAGR of about 8% through 2020-2024|Presence of High-Throughput and Novel Technologies to Boost Growth| Technavio
- The Global Biotechnology Reagents Market will grow by USD 37.87 bn during 2020-2024
- 08/04/2020
|
3M Co. stock falls Monday, underperforms market
- Shares of 3M Co. slid 0.04% to $150.41 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...
- 08/03/2020
|
COVID-19 Impacts: DNA Sequencing Market will Accelerate at a CAGR of About 19% Through 2020-2024 | Growing Adoption of NGS to Boost Growth | Technavio
- The Global DNA Sequencing Market will grow by USD 12.5 bn during 2020-2024
- 08/03/2020
|
GE Competitor Siemens Healthineers Makes Blockbuster Acquisition
- Siemens Healthineers is buying Varian Medical Systems in a $16 billion merger, marrying health-care diagnostics with therapies.
- 08/02/2020
|
3M Co. stock underperforms Friday when compared to competitors
- Shares of 3M Co. slid 1.08% to $150.47 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...
- 07/31/2020
|
Vanguard Health Care Fund Adds 3 Stocks to Portfolio
- Fund focused on health reveals 2nd-quarter trades Continue reading...
- 07/31/2020
|
3 Zacks Rank #1s Making New Highs
- 3 Zacks Rank 1s Making New Highs
- 07/31/2020
|
Thermo Fisher Long Case: Trajectory Is Clear, Buy On Value
- Strong quarter exit and clear guidance for Q4 2020 on the back of $1.3 billion in COVID-19 related sales YTD.
- 07/31/2020
|
The Danaher Juggernaut Rolls On, Crushing Valuation Concerns Under The Wheels Of Growth
- Danaher does it again, with a stronger second-quarter result driven by underlying strength in bioproduction spending and Covid-19 testing.
- 07/31/2020
|
Dover Proving That It Has Changed For The Better
- Dover posted a modest revenue beat and a strong segment-level profit beat, as the company's cost initiatives have led to materially better decremental margins in this downturn.
- 07/31/2020
|
Should You Buy Danaher Stock at Its All-Time High?
- The healthcare-focused company continues to power higher. Here's what's driving it, and why the stock can continue to appreciate.
- 07/30/2020
|
Earnings Estimates Rising for Danaher (DHR): Will It Gain?
- Danaher (DHR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 07/29/2020
|
Charting a (bullish) holding pattern, S&P 500 digests break to 5-month highs
- The major U.S. benchmarks are acting well technically, though amid increasingly sideways late-July price action, writes Michael Ashbaugh.
- 07/28/2020
|
Here's Why Danaher (DHR) is a Great Momentum Stock to Buy
- Does Danaher (DHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/28/2020
|
COVID-19 Impacts: Respiratory Syncytial Virus Diagnostics Market will Accelerate at a CAGR of almost 10% through 2020-2024 | Increase In Product Launches to Boost Growth | Technavio
|
COVID-19 Impacts: Respiratory Syncytial Virus Diagnostics Market will Accelerate at a CAGR of almost 10% through 2020-2024 | Increase In Product Launches to Boost Growth | Technavio
- The Global Respiratory Syncytial Virus (RSV) Diagnostics Market will grow by $585.17 million during 2020-2024
- 07/28/2020
|
BIBL And TPLC: How Faith-Based ETFs Score On ESG Transparency And Conviction
- In this article, I look at the holdings and supporting materials of two US large-cap ETFs based on Biblically Responsible Investing principles: the Timothy Plan and Inspire Investing ETFs.
- 07/27/2020
|
INSIGHT-The U.S. has more COVID-19 testing than most. So why is it falling so short?
- The United States might have more COVID-19 testing capacity than any other country. At the heart of the crisis is a reliance by public and private labs on automated testing equipment that locks them in to using proprietary chemical kits and other tools made by a handful of manufacturers.
- 07/27/2020
|
Global Ophthalmology Devices Market Analysis Highlights the Impact of COVID-19 2020-2024 | Increasing Prevalence of Ophthalmic Diseases to Boost Market Growth | Technavio
- The Global Ophthalmology Devices Market will grow by $ 13.03 bn during 2020-2024
- 07/27/2020
|
